Patheon 10-Q 9 Jun 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2017	May 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Patheon N.V.
Entity Central Index Key	1,643,848
Current Fiscal Year End Date	--10-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding (in shares)		145,136,214

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Current
Cash and cash equivalents	$ 92.7	$ 165
Accounts receivable, net	420.9	401
Inventories, net	451.6	395.2
Income taxes receivable	14.3	8.7
Prepaid expenses and other	24.1	21.5
Total current assets	1,003.6	991.4
Capital assets	1,169.3	983.6
Intangible assets	235.2	247.6
Deferred tax assets	30.2	29.8
Goodwill	281.4	281.6
Investments	11.2	11.5
Other long-term assets	39.2	44.1
Total assets	2,770.1	2,589.6
Current
Accounts payable and accrued liabilities	382.2	393.6
Income taxes payable	9.3	6.6
Deferred revenues - current	195.5	154.2
Current portion of long-term debt	19.4	19.5
Total current liabilities	606.4	573.9
Long-term debt	2,069.4	2,049.2
Deferred revenues	132.4	102.3
Deferred tax liabilities	96.7	67.1
Other long-term liabilities	147.7	145.5
Total liabilities	3,052.6	2,938
Commitments and contingencies
Shareholders' deficit:
Ordinary shares (par value of €0.01 per share, 500,000,000 shares authorized, 145,144,742 and 145,074,042 shares issued as of April 30, 2017 and October 31, 2016, respectively)	1.6	1.6
Additional paid in capital	602.4	591.4
Treasury shares (at cost, 8,528 ordinary shares as of April 30, 2017)	(0.2)	0
Accumulated deficit	(786.2)	(842.1)
Accumulated other comprehensive loss	(100.1)	(99.3)
Total shareholders' deficit	(282.5)	(348.4)
Total liabilities and shareholders' deficit	$ 2,770.1	$ 2,589.6

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - € / shares	Apr. 30, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	145,144,742	145,074,042
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, par value (in euros per share)	€ 0.01	€ 0.01

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Income Statement [Abstract]
Revenues	$ 483.4	$ 468.6	$ 940.8	$ 874.5
Cost of goods sold	342.7	330.3	670.4	637.3
Gross profit	140.7	138.3	270.4	237.2
Selling, general and administrative expenses	92.1	74.8	173.2	148.5
Research and development	0.4	0.6	1.1	1.3
Repositioning expenses	1.8	1.3	2.4	2.5
Acquisition and integration costs	8.1	7.6	11.6	10.2
Other operating expense (income)	0.5	1.2	4.1	(3.7)
Operating income	37.8	52.8	78	78.4
Interest expense, net	30.8	42.6	59	86.4
Foreign exchange loss, net	0.7	7.1	5.5	11.4
Refinancing expenses	6.3	0	6.3	0
Bargain purchase gain	(26.4)	0	(26.4)	0
Other loss (income), net	0.3	0.5	0.5	(1.3)
Income (loss) before income taxes	26.1	2.6	33.1	(18.1)
(Benefit from) provision for income taxes	(1.5)	0.7	(22.8)	0
Net income (loss) from continuing operations	27.6	1.9	55.9	(18.1)
Net loss from discontinued operations	0	(1)	0	(3.1)
Net income (loss)	$ 27.6	$ 0.9	$ 55.9	$ (21.2)
Basic earnings (loss) per ordinary share
From continuing operations (in USD per share)	$ 0.19	$ 0.02	$ 0.39	$ (0.16)
From discontinued operations (in USD per share)	0	(0.01)	0	(0.03)
Diluted earnings (loss) per ordinary share
From continuing operations (in USD per share)	0.19	0.02	0.38	(0.16)
From discontinued operations (in USD per share)	$ 0	$ (0.01)	$ 0	$ (0.03)
Average number of ordinary shares outstanding
Basic (in shares)	145,136,214	115,609,756	145,132,349	115,609,756
Diluted (in shares)	146,267,128	115,609,756	146,276,351	115,609,756

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income (loss)		$ 27.6	$ 0.9	$ 55.9	$ (21.2)
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments		(4.7)	14.3	(7.3)	5
Net (loss) gain related to net investment hedge		(4.6)	(25.8)	4	(18.9)
Net gain on intra-entity foreign currency transactions		0	3.8	0	3
Change in value of derivatives designated as foreign currency cash flow hedges		(3.4)	6.9	(1.1)	(1)
Losses from foreign currency hedges reclassified to consolidated statement of operations (1)	[1]	0.7	3.5	2.2	8.1
Net change in minimum pension liability	[2]	0.7	0.4	1.4	0.8
Comprehensive income (loss)		$ 16.3	$ 4	$ 55.1	$ (24.2)
[1]	1 Net of an income tax benefit of $0.1 million for the three and six months ended April 30, 2017. Income tax expense is not applicable for the six months ended April 30, 2016 as these amounts are from the Company's Canadian operations which were under a full valuation allowance in the prior period. The valuation allowance was released during the fourth quarter of fiscal 2016. Amounts, gross of tax, have been reclassified to foreign exchange loss, net on the consolidated statements of operations.
[2]	2 Net of an income tax expense of $0.0 million for the three and six months ended April 30, 2017 and 2016, which is included as a component of provision for income taxes on the consolidated statements of operations. Amounts, gross of tax, have been reclassified to cost of goods sold and selling, general and administrative expenses in the consolidated statements of operations. See Note 7 for further information.

CONSOLIDATED STATEMENTS OF COM6

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2017
Statement of Comprehensive Income [Abstract]
Losses from foreign currency hedges reclassified to consolidated statement of operations, net of income tax expense	$ 0.1	$ 0.1
Net change in minimum pension liability, net of income tax benefit	$ 0	$ 0

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT (Unaudited) - 6 months ended Apr. 30, 2017 - USD ($) $ in Millions	Total		Ordinary Shares	Additional Paid-in Capital	Treasury Shares	Accumulated Deficit	Accumulated Other Comprehensive Loss
Stockholders' equity, beginning of period (shares) at Oct. 31, 2016			145,074,042
Stockholders' equity, beginning of period at Oct. 31, 2016	$ (348.4)		$ 1.6	$ 591.4	$ 0	$ (842.1)	$ (99.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ordinary share issuances related to stock based compensation	0
Stock based compensation	11			11
Treasury shares acquired, at cost	(0.2)				(0.2)
Comprehensive income (loss):
Net income	55.9					55.9
Foreign currency translation adjustments	(7.3)						(7.3)
Net gain related to net investment hedge	4						4
Change in value of derivatives designated as foreign currency cash flow hedges	(1.1)						(1.1)
Losses from foreign currency hedges reclassified to consolidated statement of operations	2.2	[1]					2.2
Net change in minimum pension liability	1.4	[2]					1.4
Comprehensive income (loss)	55.1					55.9	(0.8)
Stockholders' equity, end of period (shares) at Apr. 30, 2017			145,136,214
Stockholders' equity, end of period at Apr. 30, 2017	$ (282.5)		$ 1.6	$ 602.4	$ (0.2)	$ (786.2)	$ (100.1)
[1]	1 Net of an income tax benefit of $0.1 million for the three and six months ended April 30, 2017. Income tax expense is not applicable for the six months ended April 30, 2016 as these amounts are from the Company's Canadian operations which were under a full valuation allowance in the prior period. The valuation allowance was released during the fourth quarter of fiscal 2016. Amounts, gross of tax, have been reclassified to foreign exchange loss, net on the consolidated statements of operations.
[2]	2 Net of an income tax expense of $0.0 million for the three and six months ended April 30, 2017 and 2016, which is included as a component of provision for income taxes on the consolidated statements of operations. Amounts, gross of tax, have been reclassified to cost of goods sold and selling, general and administrative expenses in the consolidated statements of operations. See Note 7 for further information.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Operating activities
Net income (loss) from continuing operations	$ 55.9	$ (18.1)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	61.9	53.5
Increase in deferred revenues	141.1	172.9
Amortization of deferred revenues	(137.2)	(101.3)
Non-cash interest	9.5	7.6
Change in other long-term assets and liabilities	4	2.9
Deferred income taxes	(29.7)	(0.9)
Stock based compensation expense	11	3
Gain on bargain purchase	(26.4)	0
Payment of original issue discount	(4.1)	0
Return on capital from equity investment	0	1.3
Foreign exchange loss on debt	0	2.2
Other	4.4	(5.1)
Net change in non-cash working capital balances	(69.5)	(161)
Cash provided by (used in) operating activities of continuing operations	20.9	(43)
Cash used in operating activities of discontinued operations	0	(2.9)
Cash provided by (used in) operating activities	20.9	(45.9)
Investing activities
Additions to capital assets	(99.2)	(95.1)
Acquisitions	(10.3)	0
Proceeds from sale of capital assets	0	0.1
Return of capital from equity investment	0	2.3
Cash used in investing activities of continuing operations	(109.5)	(92.7)
Cash used in investing activities of discontinued operations	0	(3.3)
Cash used in investing activities	(109.5)	(96)
Financing activities
Proceeds from borrowings	30	0.7
Repayment of debt	(9.6)	(9.9)
Increase in deferred financing costs	(2.7)	0
Treasury share purchases to satisfy certain tax withholdings	(0.1)	0
Cash provided by (used in) financing activities	17.6	(9.2)
Effect of exchange rate changes on cash and cash equivalents	(1.3)	7.1
Net change in cash and cash equivalents during the period	(72.3)	(144)
Cash and cash equivalents, beginning of period	165	328.7
Cash and cash equivalents, end of period	$ 92.7	$ 184.7

THE COMPANY

THE COMPANY	6 Months Ended
	Apr. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY	THE COMPANY Patheon N.V. (“Patheon” or "the Company") was formed on December 24, 2013, as Patheon Coöperatief U.A., a Dutch cooperative with excluded liability for its members ( coöperative met uitgesloten aansparkelijkheid ) and a wholly owned indirect subsidiary of JLL/Delta Patheon Holdings, L.P. (the “Partnership”), which in turn is owned 51% by JLL Patheon Co-Investment Fund L.P. ("JLL") and 49% by Koninklijke DSM N.V. ("DSM"). On June 3, 2016, the Company was converted into a Dutch limited liability company ( naamloze vennootschap ) and changed its name to Patheon N.V. On July 21, 2016, the Company amended its articles of association, resulting in a split of the Company's ordinary shares and a $1.2 million contribution by the Partnership to the Company's equity capital in connection with the share split. This share split and capital contribution resulted in a total of 115,609,756 ordinary shares outstanding at a par value of €0.01 per share. On July 21, 2016, the Company commenced an initial public offering ("IPO") of an additional 29,464,286 ordinary shares at a public offering price of $21.00 per share, which included 4,464,286 ordinary shares sold pursuant to the option granted to the underwriters to purchase additional ordinary shares from the Company. As part of the IPO, DSM sold 4,761,905 ordinary shares to the public that were distributed to them in connection to their ownership in the Partnership. A total of 34,226,191 ordinary shares were sold in connection to the IPO. The Company did not receive any proceeds from the ordinary shares sold by DSM. The IPO was completed on July 26, 2016. The Company received total net proceeds of approximately $584.8 million from the IPO, after deducting underwriting discounts and commissions, but before deducting estimated offering expenses. The shares offered and sold in the IPO were registered under the Securities Act pursuant to the Company's Registration Statement on Form S-1, which was declared effective by the SEC on July 18, 2016. The Company's ordinary shares began trading on the New York Stock Exchange under the symbol "PTHN" as of July 21, 2016. As of April 30, 2017 , the Company had 145,136,214 ordinary shares outstanding with a par value of €0.01 per share. Ordinary shares owned by the public constitute approximately 24% of the outstanding ordinary shares. JLL, DSM and the Partnership own approximately 38% , 34% and 4% of the Company through their ownership of outstanding ordinary shares, respectively. In accordance with the Company's articles of association, each ordinary share shall have one vote in the Company's general meeting. The Partnership's ownership comprises of shares held for the benefit of certain employees. See Note 9 for further discussion.

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation Patheon consists of three reportable segments: Drug Product Services ("DPS"), Pharmaceutical Development Services ("PDS"), and Drug Substance Services ("DSS"). Drug Product Services provides manufacturing and packaging for approved prescription, over-the-counter, and nutritional products. Pharmaceutical Development Services provides a wide spectrum of advanced formulation, production, and technical services from the early stages of a product's development to regulatory approval and beyond, as well as for new formulations of approved products for life cycle extension. Drug Substance Services provides development and manufacturing for the biologically active component of a pharmaceutical product from early development through commercial production. The accompanying unaudited consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). Operating results for the three and six months ended April 30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending October 31, 2017 ("fiscal 2017 "). These consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and therefore should be read in conjunction with the audited consolidated financial statements and notes for the fiscal year ended October 31, 2016 ("fiscal 2016 "). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect: the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenue and expenses in the reporting period. Management believes that the estimates and assumptions used in preparing its consolidated financial statements are reasonable and prudent; however, actual results could differ from those estimates. Changes in significant accounting policies As a result of early adopting Accounting Standards Update 2016-09, 'Improvements to Employee Share-Based Payment Accounting', the Company is electing to account for forfeitures on stock based compensation awards as they occur. No adjustment is required to comply with the early adoption. The Company was previously not estimating forfeitures on stock based compensation awards since the impact of potential forfeiture was immaterial to the consolidated financial statements. Segment information U.S. GAAP requires segmentation based on an entity’s internal organization and reporting of revenue and operating income (loss) based upon internal accounting methods commonly referred to as the “management approach.” Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), or decision making group, in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company’s four operating segments are: North America Drug Product Services, or North America DPS, Europe Drug Product Services, or Europe DPS, Pharmaceutical Development Services, or PDS and Drug Substance Services, or DSS. The North America DPS and Europe DPS operating segments meet the aggregation criteria to be presented as one reportable segment referred to as DPS. As a result, the Company has determined it has three reportable segments: DPS, PDS, and DSS. Corporate is not an individually reportable segment because the quantitative thresholds have not been met and as such has been reported in Other. Recently adopted accounting pronouncements Accounting Standards Update ("ASU") Description Date Adopted Improvements to Employee Share-Based Payment Accounting (ASU 2016-09) This update simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company early-adopted ASU 2016-09 during the second quarter of fiscal 2017, which had no effect on the Company's financial statements. February 1, 2017 Simplifying the Accounting for Measurement-Period Adjustment (ASU 2015-16) This update eliminated the requirement to an acquirer in a business combination to retrospectively adjust provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Instead, the update requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The impact will be dependent on future transactions. November 1, 2016 Simplifying the Presentation of Debt Issuance Costs (ASU 2015-03) The pronouncement requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with that of debt discounts. The pronouncement is being applied retrospectively and the Company's October 31, 2016 balance sheet has been adjusted. The April 30, 2017 and October 31, 2016 balance sheets were adjusted to decrease the deferred financing cost asset and decrease the long term debt liability by $45.2 million and $50.3 million, respectively. November 1, 2016 Recently issued accounting pronouncements Accounting Standards Update ("ASU") Description Expected Impact Effective Date Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (ASU 2017-07) This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost. In addition, only the service cost component will be eligible for capitalization. The amendment is applied retrospectively with earlier application permitted. We are assessing the impact to the individual line items to the Statements of Operations. The Company does not expect there to be a material impact to net income. November 1, 2018 Simplifying the Test for Goodwill Impairment (ASU 2017-04) This update simplified the subsequent measurement of goodwill by eliminating Step 2 of the goodwill impairment test. Instead, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. The amendment is applied prospectively with earlier application permitted. We do not expect to have a material impact on the Company’s financial statements. November 1, 2020 Clarifying the Definition of a Business (ASU 2017-01) This update narrows the definition of outputs and aligns it with how outputs are described in Topic 606. The amendment also provides a more robust framework to use in determining when a set of assets and activities is a business. The amendment is applied prospectively with earlier application permitted. The impact on the consolidated financial statements from the adoption of this guidance is dependent on future business combinations. November 1, 2018 Revenue from Contracts with Customers and related standards (ASU's 2014-09, 2016-08, 2016-10, 2016-12, 2016-20) This update supersedes the existing revenue recognition guidance and provides a new framework for recognizing revenue. These updates identified practical expedients and clarified various aspects of the new revenue recognition standard outlined in Accounting Standards Update 2014-09. This standard may be adopted using either a retrospective or modified retrospective method. Early adoption is permitted. We are currently in the process of evaluating the impact of this standard. It is still too early in our process to determine the magnitude of the potential impact. However, based on our preliminary assessment, we believe the timing of revenue recognition for commercial and development contracts may differ from our current revenue recognition policies. The Company is determining the magnitude of this potential change. We plan to adopt the standard on November 1, 2018, and we have not yet selected a transition method. November 1, 2018 From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above or in our audited consolidated financial statements and notes for fiscal 2016 , believes these standards will not have a material impact on the Company’s results of operations, cash flows, or financial position. A more detailed listing of recently issued accounting pronouncements are included in our audited consolidated financial statements and notes for fiscal 2016 .

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	6 Months Ended
	Apr. 30, 2017
Business Combinations [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS The acquisition activity referenced below has been accounted for using the acquisition method of accounting in accordance with ASC Subtopic 805-10, "Business Combinations," and the fair value concepts set forth in ASC Subtopic 820-10, "Fair Value Measurements and Disclosures". The total purchase price for each acquisition was allocated to the assets acquired and liabilities assumed based on their respective fair values as of the acquisition date. The allocation of the purchase price is based on estimates and assumptions that are subject to change within the measurement period. The excess of the fair values of the assets acquired and liabilities assumed over the consideration transferred was recorded as a bargain purchase gain. RCI Acquisition Background On February 1, 2017, the Company acquired the Roche Carolin, Inc. active pharmaceutical ingredients (API) facility located in Florence, South Carolina ("RCI Acquisition") from Roche Holdings, Inc. (Roche). Through the acquisition, the Company entered into a stock purchase agreement in which Roche provided amounts to satisfy certain capital expenditures and other liabilities of the facility and the Company provided an upfront payment of $1.0 million to acquire the stock of Roche Carolina Inc. (RCI) and approximately $9.3 million to acquire inventory, spare parts, prepaid expense and accounts payable and certain transaction expenses of Roche. The RCI Acquisition is included in the DSS segment. As part of the transaction, the parties entered into (i) a supply agreement for the production of certain pharmaceutical intermediates by the Company for Roche and (ii) a toll manufacturing agreement where the Company will assume the manufacturing of certain products produced by the facility. The toll manufacturing agreement has a five-year initial term. During the first four years of the term, Roche is subject to a minimum annual purchasing commitment. The Company will manufacture certain existing Roche products and sell the products back to Roche at fiscal year 2016 standard costs. Annual volumes above the minimum annual commitment will be rolled into the subsequent year. If applicable, Roche will pay true-up payments for amounts below the minimum purchase requirement. A liability from this unfavorable product supply contract has been recognized as deferred revenue in order to reflect this liability at fair value as of the acquisition date. Purchase Price Allocation The preliminary purchase price allocation for the RCI Acquisition is as follows: $ Assets Inventories 9.4 Prepaid expenses and other 0.1 Capital assets 155.6 Total assets acquired 165.1 Liabilities Accounts payable and accrued liabilities 2.0 Deferred revenue 67.0 Deferred tax liabilities 59.4 Total liabilities assumed 128.4 Total net assets 36.7 Bargain purchase gain (26.4 ) Total purchase price 10.3 The bargain purchase gain, net of taxes, is reflected in income before taxes in the statements of operations. In late 2015, Roche analyzed strategic alternatives for the facility, including potentially closing or divesting the facility. The cost to close the facility or continue operating an under utilized facility contributed to the bargain purchase gain noted above. Financial results The revenues and net income from continuing operations from the RCI Acquisition for the period from February 1, 2017 to April 30, 2017 included in the consolidated statement of operations are as follows: February 1, 2017 to April 30, 2017 $ Revenues 8.1 Net income from continuing operations (1) 25.9 (1) Net income from continuing operations includes the $ 26.4 million of the bargain purchase gain. Pro forma financial information The following unaudited supplemental pro forma information presents the financial results as if the acquisition had occurred on November 1, 2015. The unaudited supplemental pro forma information does not purport to be indicative of what would have occurred had the acquisition been completed on November 1, 2015, nor is it indicative of any future results. Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Revenues 483.4 484.0 999.1 904.9 Net income from continuing operations 1.2 (6.0 ) 11.4 (258.8 ) (1) Net income from continuing operations for the six months ended April 30, 2016 includes $257.8 million of impairment expense related to Roche's strategic realignment of the facility. This is not part of the acquisition transaction and as such is not removed from the pro forma financial information. The unaudited pro forma financial information was prepared using the acquisition method of accounting and is based on the historical financial information of the Company and RCI, reflecting the Company's and RCI's combined results of operations for the three and six months ended April 30, 2017 and 2016 . The historical financial information has been adjusted to give effect to the pro forma events that are (i) directly attributable to the RCI Acquisition, (ii) factually supportable and (iii) expected to have a continuing impact on the combined results of the Company and RCI. The unaudited pro forma consolidated results reflect primarily the following pro forma adjustments: • additional revenue related to the amortization of deferred revenue on the unfavorable product supply contract; • additional cost of goods sold resulting from increases in depreciation expense relating to the fair values of acquired property and equipment; • removal of repositioning costs related to the acquisition; and • the effect of the bargain purchase gain

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Apr. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS Banner Pharmacaps On May 12, 2015, the Company sold its Banner Pharmacaps entity in Mexico, previously included within the DPS and BLS segments, to the Perrigo Company plc for approximately $36.4 million in cash. The Banner Pharmacaps entity in Mexico produced over-the-counter and nutritional products for consumption in Mexico. The Company acquired the entity in fiscal 2012 and subsequent to this acquisition, the Company shifted its business strategy, focusing more on technological innovation and R&D. The Company recognized a gain on sale of $ 2.6 million , which included adjustments in the second quarter of 2016 primarily related to working capital adjustments. Biosolutions Operations in Capua, Italy On July 31, 2015, the Company sold its Biosolutions facility in Capua, Italy, previously included within the Biosolutions segment, for approximately €0.3 million in cash. The sale occurred as a result of a strategic shift in the Company’s long term business strategy. The Company recognized a loss on sale of $ 24.0 million , which included an adjustment in the second quarter of 2016 for future retention bonuses at the facility. DPx Fine Chemicals On August 31, 2015, the Company sold its DPx Fine Chemicals ("DFC") division, which previously comprised the DFC operating segment. DFC was sold for a cash purchase price of €179.0 million , which included a €3.0 million working capital payment made in the first quarter of 2016. The Company recognized a gain on sale of $ 107.0 million , which included an adjustment in the first quarter of 2016 for estimated taxes on the sale. The DPx Fine Chemicals division, which was acquired through the DPP Acquisition, developed chemicals that are not in line with the Company’s long term business strategy. The results of the above dispositions have been presented as discontinued operations, the results of which for the three and six months ended April 30, 2016 are as follows: Three months ended April 30, Six months ended April 30, 2016 2016 $ $ Revenues — 2.1 Cost of goods sold — 1.9 Gross profit — 0.2 Selling, general and administrative expenses — 0.4 Loss on disposals, net 0.9 2.8 Operating loss (0.9 ) (3.0 ) Foreign exchange income, net (0.1 ) (0.1 ) Loss before income taxes (0.8 ) (2.9 ) Provision for income taxes 0.2 0.2 Net loss (1.0 ) (3.1 ) The Company did not record any discontinued operations activity for the three and six months ended April 30, 2017.

SUPPLEMENTAL BALANCE SHEET INFO

SUPPLEMENTAL BALANCE SHEET INFORMATION	6 Months Ended
	Apr. 30, 2017
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION Inventories Inventories consisted of the following: April 30, 2017 October 31, 2016 $ $ Raw materials, packaging components and spare parts 228.7 192.1 Work-in-process 92.3 80.9 Finished goods 130.6 122.2 Balance, end of period 451.6 395.2 Accounts payable and accrued liabilities Accounts payable and accrued liabilities consisted of the following: April 30, 2017 October 31, 2016 $ $ Trade payables 277.1 279.3 Interest payable 9.8 14.0 Accrued salaries and related expenses 78.8 81.8 Customer deposits 4.1 4.3 Repositioning 4.9 5.4 Other accruals 7.5 8.8 Balance, end of period 382.2 393.6 Intangible assets The following table summarizes gross carrying amounts, accumulated amortization, and accumulated impairments related to the Company's identifiable intangible assets as of April 30, 2017 : Definite-lived intangible assets Gross carrying value Accumulated amortization Net carrying value Weighted Average Useful Life (in Years) $ $ $ Favorable agreements 1.0 (1.0 ) — — Trade names 1.6 (0.9 ) 0.7 5.6 Developed technology 54.1 (19.4 ) 34.7 10.8 Trade secrets and patents 2.5 (0.4 ) 2.1 14.5 Customer relationships 248.8 (49.5 ) 199.3 14.2 Non-compete agreements 2.6 (2.2 ) 0.4 3.0 Subtotal 310.6 (73.4 ) 237.2 Foreign exchange (3.3 ) Balance, end of period 233.9 Indefinite-lived intangible assets Gross carrying value Accumulated impairment Net carrying value $ $ $ In-process research and development 2.2 (0.9 ) 1.3 Regulatory permits 0.2 — 0.2 Subtotal 2.4 (0.9 ) 1.5 Foreign exchange (0.2 ) Balance, end of period 1.3 In-process research and development (“IPR&D”) is classified as definite-lived or indefinite-lived depending on whether the product has been approved and if commercialization has begun. IPR&D for products that have been approved is classified as a definite-lived intangible asset and is amortized over the life of the asset. IPR&D for products that have not been approved is classified as an indefinite-lived intangible asset and either begins to be amortized upon approval and product commercialization or is written-off if the product is not approved. In the first quarter of fiscal 2016, the Company sold an IPR&D asset to Banner Life Sciences for cash consideration equal to its net carrying value of $3.6 million . At the time of the sale, the asset had a gross carrying value of $7.9 million and had incurred $4.3 million in impairments. Goodwill The following table summarizes the changes in the carrying amount of goodwill for the six months ended April 30, 2017 : Total $ Balance at October 31, 2016 (1) 281.6 Foreign currency translation adjustments (0.2 ) Balance at April 30, 2017 281.4 (1) The opening cumulative goodwill balance is reflective of historical impairment charges of the full value of goodwill.

LONG-TERM DEBT

LONG-TERM DEBT	6 Months Ended
	Apr. 30, 2017
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Long-term debt in the accompanying consolidated balance sheets at April 30, 2017 and October 31, 2016 consists of the following: As of April 30, 2017 As of October 31, 2016 $ $ USD Term Loan at LIBOR with a floor of 1% plus 3.25% rate and maturity date of April 20, 2024 (the "Credit Agreement") 1,133.1 — Euro Term Loan at LIBOR with a floor of 1% plus 3.00% rate and maturity date of April 20, 2024 (the "Credit Agreement") 504.5 — USD Term Loan with a base rate plus 2.25% or LIBOR with a floor of 1% plus 3.25% rate and maturity date of March 10, 2021 (the "Credit Agreement") — 1,138.9 Euro Term Loan with a base rate plus 2.50% or LIBOR with a floor of 1% plus 3.50% rate and maturity date of March 10, 2021 (the "Credit Agreement") — 511.0 7.50% Senior Notes due February 1, 2022 (the "Notes") 450.0 450.0 Secured Revolving Facility balance at LIBOR plus 3.25% rate and maturity terms on a rolling basis 50.0 20.0 Government of Austria research and development loans with annual interest rates ranging from 1.56% to 2.00% and maturities through March 2020 2.7 3.5 Italian subsidized loan with annual interest rate of 0.5%, and maturity date of June 30, 2020 3.6 4.1 Italian bank loan with Euribor 6-month + 7.1% rate, and maturity date of June 30, 2020 0.7 0.7 Capital lease obligations 1.6 0.7 Total long-term debt outstanding 2,146.2 2,128.9 Less original issue discount, net of accumulated amortization of $7.1 million and $6.2 million, respectively (12.2 ) (9.9 ) Less deferred financing costs (45.2 ) (50.3 ) Less current portion (19.4 ) (19.5 ) Balance, end of the period 2,069.4 2,049.2 2017 Term Loans and Revolving Line On April 20, 2017, the Company completed the refinancing of its term loans and amended the existing revolving credit facility (the "Refinancing'") by entering into Amendment No. 4 of the original credit facility agreement dated as of March 11, 2014 (the "Credit Facility"). Under Amendment No. 4, the existing term loans were refinanced with new term loans ("Tranche B Term Loans"). The Tranche B Term Loans consisted of (i) Tranche B US Dollar Term Loans in the amount of $1.133 billion and (ii) Tranche B Euro Term Loans in the amount of €463.1 million , or $496.3 million . The Tranche B Term Loans will mature on April 20, 2024. Under Amendment No. 4, the Company increased the size of the revolver facility (the "Revolving Facility") to $250.0 million , of which up to $75.0 million is available for letters of credit. Of the total revolving commitments, $87.1 million will terminate on March 11, 2019 (the "Tranche A Commitments") and the remaining commitments (the "Tranche B Commitments") will terminate on April 20, 2022. The US Dollar denominated Tranche B Term Loans bear interest at a rate per annum equal to, at the option of the Company, a base rate plus 2.25% or LIBOR with a floor of 1% plus 3.25% . The margin applied to the base rate will be reduced to 2.0% and the margin applied to LIBOR will be reduced to 3.0% if the Company achieves, and as long as the Company maintains, a B2/Stable credit rating or better from Moody's Inventors Service, Inc. The Euro denominated Tranche B Term Loans bear interest at a rate per annum equal to LIBOR with a floor of 1% plus 3.00% . Borrowings under the Revolving Facility bear interest at a rate per annum equal to, at the option of the Company, a base rate plus 2.25% or LIBOR plus an applicable margin of 3.25% . The Company will also pay a commitment fee of 0.50% per annum on the unused portion of the Revolving Facility with a step down to 0.375% when the First Lien Leverage Ratio (as defined below) is less than or equal to 3.00 to 1.00. As of April 30, 2017 , the Company borrowed $50.0 million against the Revolving Facility, which will renew until paid. Under the Revolving Facility, the Company is required to maintain a First Lien Leverage Ratio below a certain amount for each of the Testing Periods as set forth in the Credit Agreement if the Company has borrowed 25% of the available credit on the Revolving Facility, or $62.5 million . For purposes of the Credit Agreement, a Testing Period means a single period consisting of the most recent four consecutive fiscal quarters ending on the covenant determination date. As of April 30, 2017 , the Company was not required to calculate the First Lien Leverage Ratio as the Company has not borrowed 25% or $62.5 million under the Secured Revolving Facility. The following table discloses the maximum First Lien Leverage Ratios permitted under the Credit Agreement: Testing Period Ending Maximum Ratio April 30, 2014 through October 31, 2014 6.75 to 1.00 November 1, 2014 through October 31, 2015 6.50 to 1.00 November 1, 2015 through October 31, 2016 6.25 to 1.00 November 1, 2016 through October 31, 2017 6.00 to 1.00 November 1, 2017 and thereafter 5.75 to 1.00 "First Lien Leverage Ratio" is generally defined in the Credit Agreement as the ratio of (i) the sum of the aggregate principal amount of the Company's and its restricted subsidiaries' indebtedness for borrowed money, principal amount of capital lease obligations and debt obligations evidenced by bonds, promissory notes, debentures or debt securities that is secured by a first priority lien on the collateral minus unrestricted cash and cash equivalents held by the Company and its restricted subsidiaries in each case set forth in the Credit Agreement to (ii) Consolidated EBITDA. Consolidated EBITDA is generally defined in the Credit Agreement as income (loss) from continuing operations before repositioning expenses, interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition-related costs, gains and losses on sale of capital assets, income taxes, asset impairment charges, depreciation and amortization, stock-based compensation expense, consulting costs related to the Company's operational initiatives, purchase accounting adjustments, other income and expenses, non-cash charges, expenses related to the DPP Acquisition, pro forma cost savings from operational excellence initiatives and plant consolidations, pro forma synergies from the DPP Acquisition, and proceeds from business interruption insurance, among other adjustments. Consolidated EBITDA is not equivalent to Adjusted EBITDA, which as discussed in Note 11, is the Company's measure of segment performance. The Company is required to make the following mandatory prepayments in respect of the Tranche B Term Loans: (i) 50% of Excess Cash Flow (as defined in the Credit Agreement) when the Company maintains a First Lien Leverage Ratio of greater than 4.00 to 1.00, with step downs to (a) 25% when the Company maintains a First Lien Leverage Ratio of less than or equal to 4.00 to 1.00 but greater than 3.50 to 1.00 and (b) 0% when the Company maintains a First Lien Leverage Ratio of less than or equal to 3.50 to 1.00; (ii) 100% of the net cash proceeds of certain asset sales (including insurance and condemnation proceeds), subject to thresholds, reinvestment rights and certain other exceptions; and (iii) 100% of the net cash proceeds of issuances of debt obligations, subject to certain exceptions and thresholds. "Excess Cash Flow" is generally defined as Consolidated EBITDA (as defined in the Credit Agreement) plus, (i) decreases in working capital, (ii) extraordinary or nonrecurring income or gains and (iii) certain other adjustments, minus, (a) increases in working capital, (b) cash interest, (c) cash taxes, (d) cash capital expenditures (e) scheduled debt amortization and (f) certain other adjustments. As the Excess Cash Flow calculation is performed annually, no payment is due for the six months ended April 30, 2017 . No Excess Cash Flow payment was required for fiscal 2016. The Company may voluntarily repay borrowings under the Credit Facility at any time. If the Company has failed to maintain the applicable First Lien Leverage Ratio, it may nevertheless avoid a default by (i) repaying outstanding borrowings under the Revolving Facility in an amount sufficient to avoid triggering the First Lien Leverage Ratio for that fiscal quarter or (ii) accepting a cash contribution of qualified equity in an amount which, if treated as Consolidated EBITDA, would bring the Company into compliance with the applicable First Lien Leverage Ratio for that fiscal quarter, in each case during the 11 business days following the deadline for delivery of the Company’s compliance certificate for that fiscal quarter. In addition, maintenance of the First Lien Leverage Ratio is required only with respect to the Revolving Line; the Term Loans do not directly benefit from the financial covenant and, until the Revolving Line is terminated and all outstanding borrowings thereunder are accelerated, will remain unaffected by a default under the Revolving Line that arises from the Company’s failure to maintain the applicable First Lien Coverage Ratio. The Credit Agreement contains other customary terms, including (i) representations, warranties and affirmative covenants, (ii) negative covenants (in addition to the limitation on distributions and the requirement to maintain the First Lien Leverage Ratio levels as described above), such as limitations on indebtedness, liens, mergers, acquisitions, asset sales, investments, prepayments of subordinated debt, and transactions with affiliates, in each case subject to baskets, thresholds and other exceptions, and (iii) events of default, such as for non-payment, breach of other covenants, misrepresentations, cross default to other debt, change in control, bankruptcy events, ERISA events, unsatisfied judgments and actual or asserted invalidity of guarantees or security documents. As of April 30, 2017 , the Company was in compliance with the covenants in the Credit Facility. Provided that the Company is in compliance with the First Lien Leverage Ratio test and no default under the Credit Agreement is continuing or would result therefrom, the covenant in the Credit Agreement that limits the Company's ability to pay dividends or make other distributions to its shareholders generally permits (with certain exceptions and qualifications) the Company to pay dividends or make such distributions in an aggregate amount, when taken together with the aggregate amount of any prepayment, repurchase, redemption or defeasance of subordinated indebtedness, not to exceed the greater of (x) 3.00% of Consolidated Total Assets and (y) $65.0 million and (ii) in aggregate amount not to exceed the available amount (as defined in the Credit Agreement) at such time. The Credit Facility is guaranteed by the Company and certain subsidiaries, and is secured by a first priority pledge on substantially all of the assets of the Company and the subsidiary guarantors, in each case subject to certain exceptions. 2014 Senior Unsecured Notes In February 2014, the Company issued $450.0 million in aggregate principal amount of 7.50% senior unsecured notes due February 1, 2022 (the "Notes") in a private placement, pursuant to which it entered into an indenture (the “Indenture”) with a commercial bank acting as trustee. Interest on the Notes accrues at a rate of 7.50% per annum and is payable semiannually in arrears on each February 1 and August 1, commencing on August 1, 2014. Interest is computed on the basis of a 360-day year comprised of twelve 30-day months. The Notes are generally required to be guaranteed by each of the Company’s restricted subsidiaries that guarantees the Credit Facility or that guarantees other material indebtedness of the Company or other Note guarantors. Except for offers to purchase Notes upon certain asset sales or a change in control of the Company, no mandatory redemption or sinking fund payment is required with respect to the Notes. On and after February 1, 2017, the Company may redeem all or a portion of the Notes at the applicable redemption prices set forth below (expressed as percentages of principal amount redeemed), plus unpaid interest accruing on the principal amount redeemed to the Redemption Date: Year % 2017 105.625 2018 103.750 2019 101.875 2020 and thereafter 100.000 In addition, we may redeem all of the Notes at a redemption price equal to the principal amount redeemed, plus unpaid interest accruing to the Redemption Date, upon certain adverse changes in applicable tax laws. The Notes are guaranteed by the Company and the Indenture does not require the Company to maintain compliance with any financial covenants. The Indenture does contain customary affirmative and negative covenants, including with respect to mergers, asset sales, restricted payments, restricted investments, issuance of debt and equity, liens, and affiliate transactions, subject to baskets and other exceptions. However, the Company will be exempt from many of the negative covenants if the Notes receive investment grade ratings from both Moody’s and S&P. The Indenture also contains customary events of default, such as for non-payment, breach of other covenants, misrepresentation, cross default to other material debt, bankruptcy events, unsatisfied judgments, and actual or asserted invalidity of guarantees. As of April 30, 2017 , the Company was in compliance with the covenants in the Indenture. Other Financing Arrangements During the third quarter of fiscal 2013, the Company received assistance from the Italian government in the form of two loans. One loan is a subsidized loan for approximately €6.0 million , of which the Company received €5.4 million during the third quarter of 2013 and the remaining €0.6 million in the second quarter of 2016. The subsidized loan has an annual interest rate of 0.5% , a maturity date of June 30, 2020 and amortizes in fixed semi-annual installments. The second loan is a bank loan of approximately €0.7 million , of which the Company received €0.6 million during the third quarter of 2013 and the remaining €0.1 million in the second quarter of 2016. The bank loan bears interest at a 6-month Euribor rate plus 7.1% , has a maturity date of June 30, 2020 and amortizes in six variable semi-annual installments beginning in December 2017. The Company receives research and development loans from the Austrian government. The loans hold various interest rates and have maturity dates through March 31, 2020. The aggregate current balance of these loans as of April 30, 2017 is $ 2.7 million . In May 2011, Gallus entered into an agreement with St. Louis County under the county's Chapter 100 program. Under the program, Gallus transferred title of the St. Louis location's buildings and property to St. Louis County in exchange for St. Louis County, Missouri Taxable Industrial Revenue Bonds (Chapter 100 Bonds) of equal value. Gallus then simultaneously leased back the land and facility from St. Louis County. The proceeds of principal and interest on the Chapter 100 Bonds are equal to the lease payment obligations on the Loan. This arrangement was acquired by the Company through the acquisition of Gallus Pharmaceuticals in September 2014. In August 2015, the agreement with St. Louis County was amended by the Company to extend through December 21, 2029 (originally December 21, 2021), which is consistent with the maturity date of the Chapter 100 Bonds. The Company has determined that it has a legal right of offset for the obligations under the lease agreement with the proceeds receivable from the Chapter 100 Bonds and intends to offset the balance. As a result, the offsetting amounts have not been recorded in the financial statements. The bonds require the Company to maintain a minimum level of employment throughout the term of the loan and an additional investment in the St. Louis facility of at least $47.0 million by December 31, 2019. In addition to the terms of the bonds indicated above, the Company also entered into an agreement under which it makes "Payments In Lieu Of Taxes" (PILOT) fee payments in lieu of property taxes, which is equal to 50% of the property taxes that would have otherwise been payable on the property. The PILOT fees will increase in years which the Company has not maintained the minimum number of employees as required by the agreement on a prospective basis. The Company has possessory and equitable title to the property, and at any time can purchase legal title for a nominal fee. In addition, as the holder of the bonds, the Company can waive any default on the lease payments. As the Company retains all benefits of ownership and can take title at any time, at which point the bonds it holds would be redeemed to settle its obligations under the lease agreement, the Company has concluded the land and personal property continue to be assets and are recorded on the consolidated balance sheets.

PENSION AND POST-RETIREMENT BEN

PENSION AND POST-RETIREMENT BENEFITS	6 Months Ended
	Apr. 30, 2017
Postemployment Benefits [Abstract]
PENSION AND POST-RETIREMENT BENEFITS	PENSION AND POST-RETIREMENT BENEFITS Employee future benefits The components of net periodic benefit cost from continuing operations for the defined benefit plans and other benefit plans for the three and six months ended April 30, 2017 and 2016 were as follows: Three months ended April 30, 2017 2016 Defined benefit pension plans Other benefit plans Defined benefit pension plans Other benefit plans $ $ $ $ Service cost 0.6 — 0.4 — Interest cost 1.0 — 1.3 — Expected return on plan assets (1.0 ) — (1.2 ) — Amortization of actuarial loss 0.7 — 0.4 — Net periodic benefit costs 1.3 — 0.9 — Six months ended April 30, 2017 2016 Defined benefit Other benefit Defined benefit Other benefit $ $ $ $ Service cost 1.2 — 0.9 — Interest cost 2.0 0.1 2.6 0.1 Expected return on plan assets (2.0 ) — (2.5 ) — Amortization of actuarial loss 1.4 — 0.8 — Net periodic benefit costs 2.6 0.1 1.8 0.1 Based on current information available from actuarial estimates, the Company anticipates that contributions required under its defined benefit pension plans and other benefit plans for fiscal 2017 will be approximately $ 3.9 million compared to contributions of $5.2 million that were made in fiscal 2016 . The decrease in the expected fiscal 2017 contributions compared to fiscal 2016 are primarily the result of decreased obligations on a pension plan for the Bourgoin, France facility due to a workforce reduction in fiscal 2016. Required contributions to defined benefit pension plans in future years may vary and will be dependent upon a number of variables, including the long-term rate of return on plan assets. The Company recognizes a termination liability for the Company's Italy operations. In accordance with Italian severance pay statutes, an employee benefit is accrued for service to date and is payable when the employee's employment with the Company ceases. The termination indemnity liability is calculated in accordance with local civil and labor laws based on each employee's length of service, employment category and remuneration. The Italian termination liability is adjusted annually by a cost-of-living index provided by the Italian government. Although there is no vesting period, the Italian government has established private accounts for these benefits and has required the Company to contribute $3.9 million and $3.4 million in fiscal 2017 and 2016 , respectively, to these accounts, with additional contributions in the future. The liability recorded in the consolidated balance sheets is the amount to which the employees would be entitled if their employment with the Company ceased. The related expenses for the three months ended April 30, 2017 and 2016 was $ 0.9 million and $0.7 million , respectively, and the related expenses for the six months ended April 30, 2017 and 2016 was $ 1.8 million and $ 1.4 million , respectively. The employee future benefit expense recorded in continuing operations in connection with defined benefit pension plans, other post-retirement benefit plans and the unfunded termination indemnities for the three months ended April 30, 2017 and 2016 was $ 2.2 million and $ 1.6 million , respectively. For the six months ended April 30, 2017 and 2016 , the employee future benefit expense was $4.5 million and $3.3 million , respectively.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	6 Months Ended
	Apr. 30, 2017
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per ordinary share is computed by dividing net income (loss) available to the Company by the weighted-average number of ordinary shares outstanding during the period. Diluted earnings (loss) per ordinary share is computed by dividing net income (loss) available to the Company by the weighted-average number of ordinary shares outstanding adjusted to give effect to potentially dilutive securities. The details of the computation of basic and diluted earnings (loss) per ordinary share are as follows: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 Numerator (in millions): Income (loss) from continuing operations $ 27.6 $ 1.9 $ 55.9 $ (18.1 ) Loss from discontinued operations $ — $ (1.0 ) $ — $ (3.1 ) Denominator: Weighted-average number of shares of ordinary shares - basic 145,136,214 115,609,756 145,132,349 115,609,756 Effect of dilutive securities: Restricted stock units 1,092,951 — 1,116,435 — Stock options 37,963 — 27,567 — Weighted-average number of shares of ordinary shares - diluted 146,267,128 115,609,756 146,276,351 115,609,756 Earnings (loss) per ordinary share - basic: From continuing operations $ 0.19 $ 0.02 $ 0.39 $ (0.16 ) From discontinued operations $ — $ (0.01 ) $ — $ (0.03 ) Earnings (loss) per ordinary share - diluted: From continuing operations $ 0.19 $ 0.02 $ 0.38 $ (0.16 ) From discontinued operations $ — $ (0.01 ) $ — $ (0.03 )

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
	Apr. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK BASED COMPENSATION	STOCK BASED COMPENSATION A summary of equity based compensation expense recognized during the three and six months ended April 30, 2017 and 2016 is as follows: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Management Equity Incentive Plan (MEIP) 1.9 2.0 4.2 3.0 Restricted Stock Units 4.0 — 5.3 — Stock Options 1.1 — 1.5 — Stock Based Compensation Expense 7.0 2.0 11.0 3.0 Management Equity Incentive Plan (MEIP) Prior to the IPO, the Company was a wholly-owned indirect subsidiary of the Partnership. The Partnership adopted the Management Equity Incentive Plan, or the MEIP, with an effective date of March 11, 2014. The purpose of the MEIP is to provide eligible participants with an opportunity to receive grants of profit interests in the Partnership designated as management units. The award of management units pursuant to this MEIP is intended to compensate employees of the Partnership and its subsidiaries, including the Company. The participants in the MEIP, as a group, are eligible to participate in the gain on the investment earned by JLL and DSM with respect to Patheon once certain specified distribution or return thresholds have been achieved. Upon issuance, MEIP units were subject to certain forfeiture (vesting) provisions which meant that if a holder's employment with Patheon terminated prior to the satisfaction of the applicable provision, the unvested MEIP units would be forfeited and the vested MEIP units could be converted into Class A Units in the Partnership on a cashless basis or by making an additional cash contribution in order to receive additional Class A Units ("Partnership Shares"). The aggregate number, class and tranche of management units that were issued under the MEIP was determined by the JLL/Delta Patheon GP Ltd., the general partner of the Partnership. The Partnership last issued MEIP units on December 9, 2015. As a result of the IPO and the adoption of the Patheon N.V. 2016 Omnibus Incentive Plan (the “Omnibus Plan”) described below, the Partnership will no longer grant awards under the MEIP to our employees. The granted MEIP units consist of Class B, Class C, Class D, and Class E units. From June 24, 2014 to December 9, 2015, the Partnership granted units under five different valuation tranches, with each tranche issued at the most recent quarterly valuation of the Company at the time of the grant. 71.4% of the Class B units have a four year service-based component for vesting ("Service-based Class B units") and the remaining Class B units ("Exit Event Class B units") vest if the holder is employed upon the occurrence of an Exit Event. An Exit Event is defined as the earliest to occur of (i) a change of control and (ii) in connection with or following an initial public offering, the sale or disposition by JLL of equity securities such that, immediately following such sale or disposition, JLL and its affiliates either (A) own less than 20% of the equity securities then issued and outstanding, calculated on a fully diluted basis, or (B) have received, in the aggregate, distributions in respect of such sale or distribution (together with any sale or distribution occurring prior thereto) equal to or in excess of 250% of its aggregate capital contributions made in respect of such equity securities prior to such sale or distribution. Each of the Class C, D, and E units have a performance and service condition related to vesting. These units vest upon the earlier to occur of (i) JLL receiving distributions in the aggregate equal to return on capital thresholds of 2.0 x, 2.5 x and 3.0 x, respectively, or (ii) an Exit Event, as defined above, does not occur prior to the fifth anniversary of an IPO and the return thresholds in (i) are met based on the average price of the Company's publicly traded shares for any twenty day period following the fifth anniversary of an IPO. If any employee is terminated for any reason prior the achievement of the above vesting conditions, all unvested units in any class are forfeited. A summary of the MEIP activity for the six months ended April 30, 2017 is as follows: Class B Class C Class D Class E Total Weighted Average Fair Value Outstanding as of October 31, 2016 59,290 8,470 8,470 8,470 84,700 $ 687.27 Forfeited (288 ) (50 ) (50 ) (50 ) (438 ) $ 870.09 Outstanding as of April 30, 2017 59,002 8,420 8,420 8,420 84,262 $ 686.32 Through the IPO, JLL and DSM received an aggregate return on capital of approximately 2.9x their invested capital, based on the value of ordinary shares of Patheon distributed by the Partnership to JLL and DSM at the IPO price and the value of cash and in-kind distributions made by the Partnership prior to the IPO. In connection with the IPO, a total of 6,106,540 ordinary shares ("MEIP shares") were distributed to the Partnership to be held for the benefit of the MEIP participants until an Exit Event occurs or until MEIP participants are otherwise permitted to transfer such interests in accordance with the terms of the partnership agreement of the Partnership and respective MEIP unit award agreements, at which time MEIP participants will receive their allocable distribution of MEIP shares. These shares represent the value of the MEIP units, in the aggregate, as determined under the MEIP, as a result of the distribution of ordinary shares to the limited partners of the Partnership in connection with the IPO. MEIP shares were issued to the Partnership with respect to Class B, C and D units for the first three valuation tranches as the applicable distribution threshold was achieved. No MEIP shares were allocated to the Partnership with respect to the final two valuation tranches or the Class E units, as the distribution thresholds and the 3.0x capital return threshold, respectively, were not achieved as of the IPO. Because no additional MEIP awards will be granted and because the ordinary shares were distributed to JLL and DSM prior to an Exit Event, the MEIP awards will not benefit from further appreciation of those shares. As such, the Company issued a total of 3,388,481 Restricted Share Units ("MEIP RSUs") under the Omnibus Plan in order to provide the MEIP participants with the opportunity to participate in the additional appreciation the MEIP awards could have generated if the Partnership had not distributed ordinary shares of the Company to JLL and DSM. MEIP RSUs were issued in relation to all unit classes and valuation tranches. The MEIP shares issued with respect to the Class B Units remain subject to the same vesting conditions as the Class B Units. As a result, MEIP shares issued in relation to Service-based Class B units are vested to the extent of each original MEIP grant's four year vesting schedule. The MEIP shares issued in relation to Exit Event Class B units are still subject to the defined Exit Event and are not vested. Lastly, the MEIP shares issued in relation to Class C and D units are fully vested due to their respective return thresholds being achieved through the IPO. The fair value of the MEIP shares are $21.00 , the price of the shares at the IPO. The MEIP RSUs are subject to the same time-based vesting criteria as the original MEIP awards as well as the achievement of performance criteria, which is measured by the Company’s stock price at the earlier to occur of (i) an Exit Event, as defined above, or (ii) the 5-year anniversary of the IPO, at which time all or a percentage of RSUs would settle based upon the attainment of an share price target, with the remaining percentage of RSUs (if any) forfeited. The share price target is $48.47 per share, at which 100% of the RSUs would settle on the applicable vesting date with the share price at or above the target. No RSUs would settle on the vesting date with the share price at or below the IPO price of $21.00 , with the settlement amount for a share price between $21.00 and $48.47 calculated on a pro rata basis. The estimated fair value of the MEIP RSUs are $8.41 per unit and was estimated using a Monte Carlo simulation model. On December 8, 2016, the Company entered into a separation agreement with a senior officer ("Separation Agreement"). The agreement, in part, replaced the senior officer's 196,485 MEIP RSUs with an equal amount of MEIP RSUs with similar terms but with a provision that the MEIP RSUs will vest, and the performance criteria be measured, on December 31, 2017 (the "Separation Date"). The estimated fair value of these replacement MEIP RSUs was $13.87 per unit and was estimated using a Monte Carlo simulation model. The Monte Carlo simulation model incorporated the following weighted average assumptions: Risk free interest rate 0.9 % Expected volatility 41.6 % Estimated years to exit event 2.98 The Company previously expensed the service-based Class B units using the graded vesting attribution method and is continuing to do so after the allocation of MEIP shares. In addition, the allocation of MEIP shares and MEIP RSUs in respect to the MEIP units resulted in an increase in fair value from the value attributed to the service-based Class B units at the time of the IPO, which the Company will expense on a straight line basis over the five year period following the IPO date, which represents the requisite service period of the MEIP RSUs. In total, the Company recorded $1.4 million and $2.9 million of compensation expense for the three and six months ended April 30, 2017 , respectively, relating to these units. The Company recorded $2.0 million and 3.0 million of compensation expense for the three and six months ended April 30, 2016 , respectively, relating to these units. The total unrecognized compensation expense for the Service-based Class B units is $8.5 million , which is expected to be recognized through fiscal 2021. For the Exit Event Class B units, the allocation of MEIP shares and MEIP RSUs resulted in an increased fair value which will serve as the basis for recognizing compensation expense for these units. The fair value of the MEIP RSUs will be expensed on a straight line basis over five years, starting with the IPO date. The Company recognized $0.2 million and $0.4 million of compensation expense for the three and six months ended April 30, 2017 , respectively. The fair value of the MEIP shares issued in respect of the Exit Event Class B units will remain unrecognized until an Exit Event occurs. The total unrecognized compensation expense for the MEIP shares and MEIP RSUs issued in respect of the Exit Event Class B units is $31.9 million , of which $3.4 million is expected to be recognized through fiscal 2021 and the remaining amount expensed on the occurrence of an Exit Event. In the third quarter of fiscal 2016, the Company recorded two one time compensation expenses in relation to the allocation of MEIP shares and MEIP RSUs in respect of the C, D and E units. A $9.0 million expense was recorded to account for the fair value of MEIP units that fully vested as a result of their respective return thresholds being met through the IPO. Additionally, a $1.5 million expense was recorded to account for the unvested MEIP units that were allocated MEIP RSUs, in which requisite service requirements had already been partially met at the time of the IPO. The Company reversed $0.1 million of these expenses in the second quarter of fiscal 2017 due to the Separation Agreement. In addition, the Company recognized $0.4 million and $1.0 million of compensation expense for the three and six months ended April 30, 2017 , respectively, to account for the remaining fair value of the C, D and E MEIP units and the incremental fair value that resulted from the conversion to MEIP shares and MEIP RSUs. These amounts are inclusive of $0.2 million reversed relating to the senior officer's awards that were replaced in the Separation Agreement. The compensation expense will be recorded on a straight line basis over five years. The total unrecognized compensation expense for the C, D, and E units is $8.9 million , which will be recognized through fiscal 2021. As a result of the Separation Agreement, the Company recorded $1.0 million of additional expense in the second quarter of fiscal 2017, not including a total of $0.3 million in expense reversals, as outlined above. The total unrecognized compensation expense for the replacement awards is $1.7 million , which will be recognized through the Separation Date. Patheon N.V. 2016 Omnibus Incentive Plan In July 2016, the Company adopted the Omnibus Plan in order to align the long-term financial interests of selected participants with those of our shareholders, strengthen the commitment of such persons to the Company and our affiliates, and attract and retain competent and dedicated persons whose efforts will result in our long-term growth and profitability. The Omnibus Plan provides for the issuance of options, share appreciation rights, restricted shares, restricted shares units, share bonuses, other share-based awards and cash awards to selected officers, employers, non-employee directors and consultants. Restricted Stock Units As of April 30, 2017, the Company has a total of (i) 1,366,383 restricted stock units outstanding to certain members of management and (ii) 41,635 restricted stock units to non-employee directors (collectively, the "Standard RSUs"), excluding the MEIP RSUs outlined above. The Standard RSUs granted to management vest in equal installments over three years and Standard RSUs granted to non-employee directors vest over one year or at the conclusion of the director's service to the Company. The Standard RSUs are not subject to performance based criteria and have a weighted average fair value of $ 24.79 . In the six months ended April 30, 2017, the Company issued 70,700 ordinary shares for vested restricted stock units. To satisfy certain tax withholding requirements, the Company purchased 8,528 of these shares at a weighted average vesting date fair value of $27.15 . These shares are currently being held at cost as treasury shares on the balance sheet. During the three and six months ended April 30, 2017 , $3.0 million and $4.3 million of stock compensation expense was recognized in relation to the Standard RSUs. As of April 30, 2017 , unrecognized stock compensation expense related to Standard RSUs was $29.5 million , which will be recognized through fiscal 2020. A summary of Standard RSUs activity for the six months ended April 30, 2017 is as follows: Restricted Share Units Weighted Average Grant Date Fair Value $ Outstanding as of October 31, 2016 450,184 21.00 Granted 1,028,534 26.46 Vested (70,700 ) 21.00 Outstanding as of April 30, 2017 1,408,018 24.79 As of April 30, 2017 , no Standard RSUs have been forfeited. Stock Options As of April 30, 2017, the Company has granted 1,747,750 stock options to certain members of management. The stock options were granted with a weighted average exercise price of $23.28 per share, with 1,033,465 of the granted stock options ("Regular Options") vesting equally over three years. The remaining stock options ("EBITDA Options") were granted to a senior officer and vest based on performance based criteria, using Credit Agreement Adjusted EBITDA as the performance metric. Credit Agreement Adjusted EBITDA is defined as the Company's Adjusted EBITDA, as defined in Note 11, plus pro forma cost savings, synergies and pre-acquisition results. The estimated weighted average fair value of stock options is $9.08 per option and was estimated using a Black-Scholes valuation model, using the following weighted average assumptions: Risk free interest rate 1.6 % Expected volatility 38.1 % Expected life of options (in years) 6.0 Dividend yield — % During the three and six months ended April 30, 2017 , $0.8 million and $1.2 million of stock compensation expense was recognized in relation to stock options. In the second quarter of fiscal 2017, $0.3 million of stock compensation expense was recognized for the EBITDA Options, due to a portion of the performance based criteria deemed probable as of April 30, 2017 . As of April 30, 2017 , total unrecognized compensation expense related to unvested Regular Options was $8.1 million , which is expected to be recognized through fiscal 2020, and total unrecognized compensation expense for the unvested EBITDA Options was $5.6 million , which will be recognized over the requisite service period when the performance based criteria is deemed probable to occur. A summary of stock option activity for the six months ended April 30, 2017 is as follows: Stock Options Weighted Average Fair Value $ Outstanding as of October 31, 2016 1,021,584 8.29 Granted 726,166 10.18 Outstanding as of April 30, 2017 1,747,750 9.08 As of April 30, 2017 , no stock options have been forfeited or exercised.

FINANCIAL INSTRUMENTS, FAIR VAL

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT	6 Months Ended
	Apr. 30, 2017
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT	FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT The Company has determined the estimated fair values of its financial instruments based on appropriate valuation methodologies; however, considerable judgment is required to develop these estimates. The fair values of the Company's financial instruments are not materially different from their carrying values. Fair value measurements The Company classifies and discloses its fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: (a) quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1); (b) inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices) (Level 2); and (c) inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3). The fair value is principally applied to financial assets and liabilities such as derivative instruments consisting of foreign exchange forward contracts, available-for-sale securities relating to Republic of Austria bonds, held-for-trading securities relating to the Company's U.S. deferred compensation plan, and a liability relating to an earnout payment on future Biologics operating results. The following table provides a summary of the financial assets and liabilities that are measured at fair value as of April 30, 2017 and October 31, 2016 : Fair value measurement at April 30, 2017 Fair value measurement at October 31, 2016 Assets measured at fair value Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total $ $ $ $ $ $ $ $ Available-for-sale securities 1.4 — — 1.4 1.4 — — 1.4 Held-for-trading securities — 1.5 — 1.5 — 1.4 — 1.4 Total assets 1.4 1.5 — 2.9 1.4 1.4 — 2.8 Fair value measurement at April 30, 2017 Fair value measurement at October 31, 2016 Liabilities measured at fair value Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total $ $ $ $ $ $ $ $ Foreign exchange forward contracts — 1.8 — 1.8 — 2.7 — 2.7 Earnout liability — — 37.9 37.9 — — 33.8 33.8 Total liabilities — 1.8 37.9 39.7 — 2.7 33.8 36.5 Level 1 - Based on quoted market prices in active markets. Level 2 - Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly. Level 3 - Unobservable inputs that are not corroborated by market data. The following table presents the fair value of the Company's financial instruments and their classifications on the consolidated balance sheets as of April 30, 2017 and October 31, 2016 : Assets as of April 30, 2017 Assets as of October 31, 2016 Balance sheet location Fair value Balance sheet location Fair value $ $ Available-for-sale securities Investments 1.4 Investments 1.4 Held-for-trade securities Investments 1.5 Investments 1.4 Total 2.9 2.8 Liabilities as of April 30, 2017 Liabilities as of October 31, 2016 Balance sheet location Fair value Balance sheet location Fair value $ $ Foreign exchange forward contracts Accounts payable and accrued liabilities 1.8 Accounts payable and accrued liabilities 2.7 Earnout liability Other long-term liabilities 37.9 Other long-term liabilities 33.8 Total 39.7 36.5 The Company has the option to net settle its derivatives with the counter party under the terms of its contracts and as such any unrealized positions are recorded net. As of April 30, 2017 , the Company had gross unrealized losses of $2.0 million and gross unrealized gains of $0.2 million under its derivative contracts. As of October 31, 2016 , the Company had gross unrealized losses of $2.7 million and gross unrealized gains of less than $0.1 million under its derivative contracts. Long-term obligations As of April 30, 2017 , the fair values and carrying values of the Company’s long-term debt, including the current portion of long-term debt, are categorized in the table below: Fair Value Level 1 Level 2 Level 3 Total Carrying Value $ $ $ $ $ Long-term debt, including current portion — 2,179.3 — 2,179.3 2,134.0 As of October 31, 2016 , the fair values and carrying values of the Company’s long-term debt, including the current portion of long-term debt, are categorized in the table below: Fair Value Level 1 Level 2 Level 3 Total Carrying Value $ $ $ $ $ Long-term debt, including current portion — 2,156.8 — 2,156.8 2,119.0 The fair value of the Company's long-term debt, including the current portion of long-term debt, is based on the quoted market prices for the same issues or on the current rates offered for debt of similar remaining maturities. Foreign exchange forward contracts and other arrangements The Company utilizes financial instruments to manage the risk associated with fluctuations in foreign exchange and interest rates. The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk management objective and strategy for undertaking various hedge transactions. As of April 30, 2017 , the Company's Canadian operations had entered into foreign exchange forward contracts to sell a net aggregate amount of $ 64.0 million U.S. dollars. These contracts hedge the Canadian operations expected exposure to U.S. dollar denominated receivables and mature at the latest on March 15, 2018 , at an average exchange rate of $ 1.3254 Canadian dollars per U.S. dollar. The mark-to-market value of these financial instruments as of April 30, 2017 was a net unrealized loss of $ 1.8 million , which has been recorded in accumulated other comprehensive income in shareholders' deficit, net of associated income tax. The Company acquired a portion of its Biologics business from DSM ("the DPP acquisition") in March 2014. In connection with the DPP acquisition, DSM was entitled to receive certain additional future contingent payments based on the performance of the acquired biologics business (the "earnout"). Under the terms of the original contribution agreement, the earnout only related to the DSM biologics business acquired in March 2014 and the earnout liability was payable by the Partnership, the parent of the Company before the Company's IPO on July 21, 2016. The value of the earnout liability as of January 29, 2016 was $36.0 million . On January 29, 2016, the Company, the Partnership, JLL, and DSM entered into an agreement (the "Earnout Agreement") whereby the Partnership’s earnout liability was legally assigned to the Company. The assignment of the liability from the Partnership to the Company was deemed a capital transaction with the Partnership of $36.0 million . Concurrently, the calculation of the earnout consideration was revised to include the future earnings of the Company’s entire biologics business ("Biologics Adjusted EBITDA"), which includes biologics business acquired in connection with a September 2014 acquisition of Gallus Pharmaceuticals. As a result of executing this Earnout Agreement, the Company will pay additional consideration to DSM based on the achievement of certain Biologics Adjusted EBITDA targets, as defined in the Earnout Agreement, of the Company’s biologics business at the conclusion of the 2020 fiscal year. If the Company sells or disposes of the biologics business prior to the end of the 2020 fiscal year, Biologics Adjusted EBITDA will be calculated by applying a 10% compounded annual growth rate through the remaining period ending October 31, 2020 to the Biologics Adjusted EBITDA for the twelve-month period ended on the last day of the month immediately preceding the date of such sale or disposition. The Company's maximum and minimum payments to DSM under the terms of the Earnout Agreement is $60.0 million and $25.0 million , respectively. Using the revised earnout definition, the value of the earnout liability as of January 31, 2016 was $31.1 million and resulted in the Company recognizing income of $ 4.9 million in the first quarter of fiscal 2016. The Company estimated the value of the earnout by valuing the three payout tranches. The first tranche of the $25.0 million minimum earnout payment, which is not contingent to Biologics Adjusted EBITDA performance, was estimated by discounting the $25.0 million using cost of debt of the Company. The values of the remaining two tranches, (i) an additional $25.0 million earnout payment which will be realized gradually as Biologics Adjusted EBITDA reaches $98.0 million , and (ii) an additional $10.0 million earnout payment which will be achieved gradually as Biologics Adjusted EBITDA approaches $110.0 million , were estimated using an option pricing framework, where the Company used a modified Black-Scholes model. The Company adjusted the earnout value to its estimated fair value as of April 30, 2017 to $37.9 million . The Company recorded $ 0.5 million and $ 4.1 million of expense in the three and six months ended April 30, 2017 , respectively, relating to marking the liability to its estimated fair value. The Company recorded $ 1.2 million of expense and $ 3.7 million of income in the three and six months ended April 30, 2016 , respectively, relating to marking the liability to its estimated fair value. The April 30, 2017 earnout valuation applies an asset volatility of 30% and an asset beta of 0.9 . A 1% change in asset volatility would have an impact on the value of +/- $0.3 million while a 0.1 change in beta would have an impact on the value of +/- $0.3 million . Assumptions are Level 3 in nature. The earnout liability activity is summarized as follows for the six months ended April 30, 2017 : Total $ Balance at October 31, 2016 33.8 Change in fair value 4.1 Balance at April 30, 2017 37.9 The change in fair value relating to the earnout is recorded in other operating income on the consolidated statements of operations. Risks arising from financial instruments and risk management The Company's activities expose it to a variety of financial risks: market risk (including foreign exchange and interest rate), credit risk and liquidity risk. The Company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company's financial performance. The Company uses derivative financial instruments to hedge certain risk exposures. The Company does not purchase any derivative financial instruments for speculative purposes. Financial risk management is the responsibility of the Company's corporate treasury. The corporate treasury works with the Company's operational personnel to identify, evaluate and, where appropriate, hedge financial risks. The Company's corporate treasury also monitors material risks and discusses them with the Audit Committee of the Board of Directors. Foreign exchange risk As of April 30, 2017 , the Company operated in Canada, the United States, Italy, France, the United Kingdom, The Netherlands, Australia, Germany, Austria, and Japan. Foreign exchange risk arises because the value of the local currency receivable or payable for transactions denominated in foreign currencies may vary due to changes in exchange rates ("transaction exposures") and because the non-U.S. dollar denominated financial statements of the Company may vary on consolidation into the reporting currency of U.S. dollars ("translation exposures"). The Company's most significant transaction exposure is from its Canadian operations. Approximately 90% of the cash receipts and 15% of the cash outflows relating to Canadian operations are transacted in U.S. dollars. As a result, the Company may experience transaction exposures because of volatility in the exchange rate between the Canadian and U.S. dollar. Based on the Company's current U.S. denominated net inflows, as of April 30, 2017 , fluctuations of +/- 10% would, everything else being equal, have an effect on year to date income before income taxes of approximately +/- $5.8 million , prior to hedging activities. The objective of the Company's foreign exchange risk management activities is to minimize transaction exposures and the resulting volatility of the Company's earnings. The Company manages this risk by entering into foreign exchange contracts. As of April 30, 2017 , the Company has entered into foreign exchange contracts to cover approximately 68% of its Canadian-U.S. dollar cash flow exposures for the next twelve months. The amount of the Company's Euro denominated debt designated as a hedge against its net investment in its subsidiaries in Austria, The Netherlands, Germany, France and Italy, is €463.1 million as of April 30, 2017 . This hedge was originally designated in March 2014 as a part of the Company's acquisition of manufacturing sites from DSM and is re-designated on a quarterly basis. As of April 30, 2017 , the balance of the net investment hedge was $ 74.7 million and is included in accumulated other comprehensive income in shareholders' deficit. Any unrealized exchange losses are included in the consolidated statement of operations due to ineffectiveness. The following table summarizes the net investment hedge foreign exchange activity for the three and six months ended April 30, 2017 and 2016 since net investment hedge inception: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Foreign exchange (loss) gain for the period from net investment hedge (4.6 ) (29.0 ) 4.0 (21.0 ) Release of ineffective portion of net investment hedge to consolidated statement of operations — 3.3 — 2.2 Net (loss) gain to other comprehensive income for the period related to net investment hedge (4.6 ) (25.7 ) 4.0 (18.8 ) Translation gains and losses related to certain foreign currency denominated intercompany loans are included as part of the net investment in certain foreign subsidiaries, and are included in accumulated other comprehensive income in shareholders' deficit. The following table summarizes the foreign currency activity on the intercompany loans that are included as part of the net investment in certain foreign subsidiaries for the three and six months ended April 30, 2017 and 2016 since net investment hedge inception: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Foreign exchange gain for the period from long-term intercompany loan revaluation — 3.8 — 3.0 Credit risk Credit risk arises from cash and cash equivalents held with banks and financial institutions, derivative financial instruments (foreign exchange contracts with positive fair values), and credit exposure to customers, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company regularly assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Management also regularly monitors the utilization of credit limits. In cases where the credit quality of a customer does not meet the Company's requirements, a cash deposit is received before any services are provided. As of April 30, 2017 and October 31, 2016 , the Company held deposits of $ 4.1 million and $ 4.3 million , respectively. Liquidity risk Liquidity risk arises when financial obligations exceed financial assets available at a particular point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at all times. The Company mitigates liquidity risk by maintaining cash and cash equivalents on-hand and through the availability of funding from credit facilities. As of April 30, 2017 , the Company was holding cash and cash equivalents of $ 92.7 million and had undrawn lines of credit available to it of $209.3 million .

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company’s four operating segments are: North America DPS, Europe DPS, PDS and DSS. The North America DPS and Europe DPS operating segments meet the aggregation criteria to be presented as one DPS reportable segment. As a result, the Company has three reportable segments: DPS, PDS and DSS. Costs relating to Corporate operations are classified as Other. The DPS segment includes commercial manufacturing outsourcing services, the PDS segment includes pharmaceutical development services, and the DSS segment includes active pharmaceutical ingredients and pharmaceutical intermediates. Corporate expenses primarily relate to general, administrative and sales and marketing expenses related to the corporate organization. These expenses are centrally directed and controlled and are not included in internal measures of segment operating performance. The CODM does not evaluate its operating segments using discrete asset information. Three months ended April 30, 2017 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 297.2 57.8 129.2 — (0.8 ) 483.4 Adjusted EBITDA 77.4 18.4 26.1 (27.5 ) (0.2 ) 94.2 Depreciation and amortization 15.4 1.9 16.1 0.9 34.3 Capital expenditures 19.5 1.7 11.6 7.4 40.2 Three months ended April 30, 2016 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 287.4 53.4 127.9 — (0.1 ) 468.6 Adjusted EBITDA 72.7 16.7 30.8 (22.2 ) 98.0 Depreciation and amortization 14.9 1.3 10.2 0.6 27.0 Capital expenditures 11.7 5.9 9.0 4.3 30.9 Six months ended April 30, 2017 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 572.4 110.1 259.1 — (0.8 ) 940.8 Adjusted EBITDA 138.8 34.7 58.1 (54.7 ) (0.2 ) 176.7 Depreciation and amortization 30.7 3.7 25.8 1.7 61.9 Capital expenditures 56.4 3.1 29.5 10.2 99.2 Six months ended April 30, 2016 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 545.9 101.9 226.8 — (0.1 ) 874.5 Adjusted EBITDA 127.8 30.5 45.6 (46.9 ) 157.0 Depreciation and amortization 29.7 2.5 20.1 1.2 53.5 Capital expenditures 56.7 15.6 16.3 6.5 95.1 The Company evaluates the performance of its segments based on segment Adjusted EBITDA. The Company's Adjusted EBITDA is income (loss) from continuing operations before repositioning expenses (including certain product returns and inventory write-offs recorded in gross profit), interest expense, foreign exchange losses reclassified from other comprehensive income (loss), refinancing expenses, acquisition and integration costs (including certain product returns and inventory write-offs recorded in gross profit), gains and losses on sale of capital assets, Biologics earnout income and expense, income taxes, impairment charges, remediation costs, depreciation and amortization, stock-based compensation expense, consulting costs related to our operational initiatives, purchase accounting adjustments, acquisition-related litigation expenses and other income and expenses. Adjusted EBITDA is one of several metrics used to measure segment operating performance and is also used to determine executive compensation. "Adjusted EBITDA margin" is Adjusted EBITDA as a percentage of revenues. The Company's presentation of Adjusted EBITDA may not be comparable to similarly-titled measures used by other companies and is not equivalent to "Consolidated EBITDA" as defined in the Credit Agreement (as discussed in Note 5). Below is a reconciliation of Adjusted EBITDA to its most comparable U.S. GAAP measure. Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Total Adjusted EBITDA 94.2 98.0 176.7 157.0 Depreciation and amortization (34.3 ) (27.0 ) (61.9 ) (53.5 ) Repositioning expenses (1) (2.2 ) (1.3 ) (3.5 ) (2.5 ) Acquisition and integration costs (8.1 ) (7.6 ) (11.6 ) (10.2 ) Interest expense, net (30.8 ) (42.6 ) (59.0 ) (86.4 ) Benefit from (provision for) income taxes 1.5 (0.7 ) 22.8 — Refinancing expenses (6.3 ) — (6.3 ) — Operational initiatives related consulting costs (1.4 ) (1.9 ) (2.5 ) (3.3 ) IPO costs — (0.4 ) — (0.8 ) Acquisition related litigation expenses (3.7 ) (0.9 ) (6.0 ) (1.9 ) Stock based compensation expense (7.0 ) (2.0 ) (11.0 ) (3.0 ) FDA remediation costs — (10.1 ) — (18.5 ) Environmental remediation costs — — (3.7 ) — Bargain purchase gain 26.4 — 26.4 — Other (0.7 ) (1.6 ) (4.5 ) 5.0 Net income (loss) from continuing operations 27.6 1.9 55.9 (18.1 ) (1) Repositioning expenses for the three and six months ended April 30, 2017 includes $0.4 million and $1.1 million of inventory reserves related to the Swindon wind down recorded in cost of goods sold. As illustrated in the table below, revenues are attributed to countries based on the location of the customer's billing address, capital assets are attributed to the country in which they are located and goodwill is attributed to the country in which the entity to which the goodwill pertains is located: Three months ended April 30, 2017 Canada US* Europe Other** Total $ $ $ $ $ Revenues 4.2 282.8 167.9 28.5 483.4 * Includes Puerto Rico ** Primarily includes Japan Three months ended April 30, 2016 Canada US* Europe Other** Total $ $ $ $ $ Revenues 5.1 317.6 124.8 21.1 468.6 * Includes Puerto Rico ** Primarily includes Japan As of and for the six months ended April 30, 2017 Canada US* Europe Other** Total $ $ $ $ $ Revenues 11.2 564.7 320.7 44.2 940.8 Capital Assets 100.1 687.6 367.5 14.1 1,169.3 Goodwill 2.5 269.4 7.4 2.1 281.4 * Includes Puerto Rico ** Other revenues primarily include Japan As of and for the six months ended April 30, 2016 Canada US* Europe Other** Total $ $ $ $ $ Revenues 12.4 589.4 236.7 36.0 874.5 Capital Assets 100.8 487.3 341.6 16.1 945.8 Goodwill 2.8 269.4 7.7 2.2 282.1 * Includes Puerto Rico ** Other revenues primarily include Japan

REPOSITIONING EXPENSES

REPOSITIONING EXPENSES	6 Months Ended
	Apr. 30, 2017
Restructuring and Related Activities [Abstract]
REPOSITIONING EXPENSES	REPOSITIONING EXPENSES During the three and six months ended April 30, 2017 , the Company incurred $1.8 million and $ 2.4 million in repositioning expenses, respectively, primarily from severance payments resulting from operational initiatives. In addition, the Company recorded inventory reserves of $0.4 million and $1.1 million for the three and six months ended April 30, 2017 relating to raw material and work in process inventory associated with the final phase of the winding down of the older section of the Swindon facility ("Swindon wind down") to allow us to re-purpose that area, which was expensed through cost of goods sold. During the three and six months ended April 30, 2016 , the Company incurred $1.3 million and $ 2.5 million in repositioning expenses, primarily from severance payments resulting from a realignment of DPS operations. The following is a summary of these expenses and other charges associated with operational improvements as of and for the three and six months ended April 30, 2017 and 2016 : As of and for the three months ended April 30, 2017 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at January 31, 2017 4.6 Employee-related expenses 1.7 — — 0.1 1.8 Repositioning expenses paid (1.6 ) Foreign exchange 0.1 Total repositioning liability at April 30, 2017 4.9 As of and for the three months ended April 30, 2016 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at January 31, 2016 4.9 Employee-related expenses 1.6 — — — 1.6 Consulting, professional and project management costs (0.3 ) — — — (0.3 ) Total expenses 1.3 — — — 1.3 Repositioning expenses paid (3.1 ) Foreign exchange 0.3 Total repositioning liability at April 30, 2016 3.4 As of and for the six months ended April 30, 2017 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at October 31, 2016 5.4 Employee-related expenses 1.9 — — 0.5 2.4 Repositioning expenses paid (3.1 ) Foreign exchange 0.2 Total repositioning liability at April 30, 2017 4.9 The balance of repositioning liabilities as of April 30, 2017 was recorded in accounts payable and accrued liabilities on the consolidated balance sheet. The Company does not have any long-term repositioning liabilities as of April 30, 2017 . As of and for the six months ended April 30, 2016 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at October 31, 2015 22.9 Employee-related expenses 2.8 — — — 2.8 Consulting, professional and project management costs (0.3 ) — — — (0.3 ) Total expenses 2.5 — — — 2.5 Repositioning expenses paid (21.8 ) Foreign exchange (0.2 ) Total repositioning liability at April 30, 2016 3.4 The balance of repositioning liabilities as of April 30, 2016 was recorded in accounts payable and accrued liabilities on the consolidated balance sheet. The Company does not have any long-term repositioning liabilities as of April 30, 2016 .

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Apr. 30, 2017
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES Related Party Transactions JLL Partners The Company has a service agreement with JLL Partners Inc. and some JLL Partners affiliates whereby the Company will reimburse the parties for management, consulting, financial, and other business services provided under the agreement. The amounts spent on these services, as well as the amounts payable outstanding in relation to these services, are shown in the tables below. DSM The Company has transition service agreements ("TSAs") with DSM resulting from the DPP Acquisition whereby DSM performs certain shared service functions on behalf of the Company. Additionally, the Company performs certain services on behalf of DSM. The revenue and expenses relating to these services, as well as the accounts receivable and payable outstanding in relation to these services, are shown in the tables below. BLS The Company has a management service agreement with BLS whereby the Company will provide various management, financial, legal and other business services to BLS. The expenses relating to these services are charged to BLS and the related accounts receivable outstanding in relation to these services are shown in the tables below. We performed production services for BLS in the first quarter of fiscal 2016 before BLS sold their commercial business to a third party. Three months ended April 30, Six months ended April 30, Revenues/Expenses 2017 2016 2017 2016 $ $ $ $ JLL Partners Expenses 0.1 0.1 0.1 0.2 DSM Revenues 0.1 0.8 0.3 0.9 DSM Expenses 1.9 2.5 5.1 5.2 Banner Life Sciences Revenues 0.7 1.4 0.7 7.9 Balances as of Accounts Receivable/Payable Balances April 30, 2017 October 31, 2016 $ $ JLL Partners Accounts Payable 0.1 — DSM Accounts Receivable 0.1 0.4 DSM Accounts Payable 1.7 0.2 Banner Life Sciences Accounts Receivable 1.2 1.1 Equity Method Investments Banner Life Sciences In October 2015, the Company invested $5.0 million in Banner Life Sciences. The investment resulted in Banner Life Sciences becoming a variable interest entity, but the entity is not consolidated as the Company does not have the ability to control the entity and therefore does not have the power to direct Banner Life Sciences' activities. The Company's maximum exposure to loss relating to this variable interest entity is limited to the carrying value of the investment. The investment is presented within investments in the consolidated balance sheets. In March 2016, the Company received a $2.4 million cash distribution from Banner Life Sciences. Percivia The Company holds a 50.0% interest in Percivia, a limited liability company for the purpose of performing research and development activities and licensing certain technology. In February 2016, the Company received a $1.2 million return of capital from Percivia in the form of a cash distribution. Chemiepark The Company holds a 47.5% interest in Chemiepark, a company tasked with providing fire protection for the chemicals site in Linz, Austria. Values as of Equity Method Investment Values April 30, 2017 October 31, 2016 $ $ Banner Life Sciences 2.5 2.9 Percivia 5.7 5.7 Chemiepark 0.1 0.1 Total 8.3 8.7 Investment carrying values are presented within investments in the consolidated balance sheets. Three months ended April 30, Six months ended April 30, Equity Method (Loss)/Gain 2017 2016 2017 2016 $ $ $ $ Banner Life Sciences (0.2 ) (0.5 ) (0.3 ) 1.3 Percivia — 0.1 — 0.2 Total (0.2 ) (0.4 ) (0.3 ) 1.5 Equity method earnings are presented within other income in the consolidated statement of operations.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Apr. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company accounts for income taxes under FASB ASC 740, Income Taxes ("ASC 740"). The Company calculates its quarterly tax provision consistent with the guidance provided by ASC 740-270, whereby the Company forecasts its estimated annual effective tax rate then applies that rate to its year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. The Company has recorded valuation allowances against certain Netherlands and other foreign jurisdictions due to insufficient evidence supporting the Company's ability to use these assets in the future. For the six months ended April 30, 2017 and 2016 , the Company recorded a benefit from income taxes in continuing operations of $ 22.8 million and $ 0.0 million , respectively. The increase in tax benefit for the six months ended April 30, 2017 was primarily attributable to changes in the Company’s jurisdictional combination of pre-tax income, the Company’s change in tax classification of a United States subsidiary ("US subsidiary") and changes to other discrete tax items, which may have unique tax implications, depending on the nature of the item. In the first quarter of fiscal 2017, the Company filed an election to change the tax classification of a US subsidiary from a partnership to an association taxable as a corporation. As a result of the change in tax classification, the Company recognized a $28.3 million deferred tax benefit related to the change in its deferred tax assets and liabilities. The Company previously accounted for the deferred tax basis difference using outside basis of the partnership's investments. The Company derecognized the deferred tax liability for the outside basis difference and recognized deferred tax assets and liabilities for existing temporary differences between the tax basis and financial reporting basis of the assets and liabilities of the subsidiary. In the second quarter of fiscal 2017, the Company amended prior year federal and state returns, originally filed by a predecessor owner, for a U.S. subsidiary. As a result of the amended returns, the Company recognized a $ 3.5 million deferred tax benefit for an increase in net operating losses. Valuation allowances are provided to reduce the related deferred income tax assets to an amount which will, more likely than not, be realized. As of April 30, 2017 , the Company has multiple subsidiaries that continue to maintain either full or a partial valuation allowances on their deferred tax assets as there is not sufficient evidence to support the reversal of all or some portion of these allowances. However, given current and anticipated future earnings in the Company's Austrian subsidiaries, the Company believes that within the next twelve months there is a reasonable possibility positive evidence will become available that would require the release of all or a portion of the valuation allowance recorded at the Company’s Austrian subsidiaries. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits within the provision for income taxes on the consolidated statement operations. As of April 30, 2017 , the Company did not have a material change in the total amount of unrecognized tax positions and does not expect a material change over the next twelve months. The Company early adopted ASU No. 2016-09 "Improvements to Employee Share-Based Payment Accounting" during the second quarter of fiscal 2017. ASU 2016-09 eliminates the requirement for additional paid in capital ("APIC") pools and requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. The adoption of ASU 2016-09 had no financial statement impact on the Company.

OTHER INFORMATION

OTHER INFORMATION	6 Months Ended
	Apr. 30, 2017
Other Information [Abstract]
OTHER INFORMATION	OTHER INFORMATION Foreign exchange During the three and six months ended April 30, 2017 , the Company recorded a foreign exchange loss of $0.7 million and $ 5.5 million , respectively. These amounts resulted from hedge and operating exposures. During the three and six months ended April 30, 2016 , the Company recorded foreign exchange losses of $7.1 million and $ 11.4 million , respectively Management Incentive Plan On March 11, 2014, the Company adopted the Management Long-Term Incentive Plan (the "LTIP") to provide long-term incentives to select key management employees of Patheon and its subsidiaries who have contributed and are expected to contribute materially to the success of the Company, and to reward outstanding performance by such employees. Leadership, key positions or identified key talent may be invited to participate in the LTIP during an identified plan year. Compensation is payable under this plan upon an Exit Event by the controlling investors of the Company (JLL and DSM), if the participant is still employed by the Company, or a qualifying termination, as defined. An Exit Event is defined as the earlier of: (a) a change of control, and (b) in connection with or following an Initial Public Offering ("IPO"), the sale or disposition by JLL or any of its affiliates of equity securities such that, immediately following such sale or disposition, either (i) JLL and its affiliates own less than 20% of the outstanding equity securities of the Partnership or the Partnership offeror, calculated on a fully-diluted basis, or (ii) JLL and its affiliates have received, in the aggregate, distributions in respect of such sale or disposition (together with any sale or disposition occurring prior thereto) equal to or in excess of 250% of the initial capital contributions and any additional capital contributions made by JLL and its affiliates for all equity securities of the Partnership or the Partnership offeror held by JLL and its affiliates prior to such sale or disposition. Not later than 90 days following commencement of each applicable Company fiscal year that would end during the term of the LTIP, the compensation committee of the board of directors of the Company (the "Compensation Committee") will determine, in its sole and absolute discretion, with respect to such fiscal year, (i) the Participants (as defined in the LTIP) with respect to that fiscal year, (ii) the EBITDA Target (as defined in the LTIP), and (iii) the targeted amount of each Award. Each award shall be evidenced by a written notice and shall be deemed granted on the first day of the fiscal year with respect to which the Compensation Committee resolves to grant such award (the "Grant Date"). Awards are denominated as a percentage of the Participant’s base salary, with the target percentage based on the Participant’s level within the organization, as determined by the Compensation Committee in its sole and absolute discretion. All awards will be paid in the form of cash, or other property having a value equal to such cash payment, as determined by the Compensation Committee in its sole and absolute discretion. Under the LTIP, the Company has granted $9.6 million in outstanding awards from March 11, 2014 through April 30, 2017 , all of which vest over a five -year period. Through April 30, 2017 , the Company has paid out $0.2 million in payments due to qualified terminations. The Company does not accrue for the overall payout as the Exit Event is deemed to not be probable until the actual occurrence of the event. Contingencies Procaps Antitrust Matter On December 10, 2012, Procaps S.A. (‘‘Procaps’’) filed a complaint against the Company in the United States District Court for the Southern District of Florida (the ‘‘District Court’’) (Case No. 12-cv-24356-DLG). The complaint involves the Company’s collaboration agreement with Procaps, pursuant to which both companies agreed to work together with respect to the marketing of a line of certain prescription pharmaceutical soft-gel development and manufacturing services. Procaps alleges that the Company’s acquisition of Banner, a business that historically has generated less than 10% of its revenues from softgel services for prescription pharmaceuticals, transformed the collaboration agreement into an anticompetitive restraint of trade and an agreement between direct competitors to set prices, divide markets and/or allocate geographic territories. Procaps seeks (i) a declaratory judgment that the collaboration agreement must cease and/or terminate; (ii) an injunction requiring that Patheon divest all of Banner’s soft-gel manufacturing capabilities; and (iii) monetary damages under federal and state antitrust and unfair competition laws, including treble damages for violations of the Sherman Act. Patheon subsequently answered Procaps’ complaint and filed its affirmative defenses to the complaint. In July 2014, upon Motion for Summary Judgment by Patheon, the court dismissed Procaps’ unfair competition claims, leaving only the antitrust claims in dispute. In March 2015, the court ordered trial to commence on November 16, 2015. In October 2015, the court granted Patheon’s motion for summary judgment with respect to all of Procaps’ remaining claims in this matter. In November 2015, Procaps filed a notice of appeal with the United States Court of Appeals for the Eleventh Circuit (the ‘‘11th Circuit Court’’). Procaps filed its initial brief with the 11th Circuit Court in February 2016 and we filed our reply brief in May 2016. Procaps filed its reply to our reply brief in June 2016. The 11th Circuit Court heard oral argument in this matter in November 2016 and in December 2016 affirmed the District Court's decision in favor of Patheon. In May 2016, Procaps filed a request for arbitration with the International Court of Arbitration of the International Chamber of Commerce. The request for arbitration involves the above-mentioned collaboration agreement. Procaps alleges that (i) Patheon’s acquisition of Banner violated the exclusivity provision of the collaboration agreement, (ii) Patheon failed to return or destroy confidential information of Procaps, (iii) Patheon was unjustly enriched by obtaining the benefit of such confidential information to which it was not entitled, and (iv) Patheon breached implied duties of good faith and fair dealing in carrying out the collaboration agreement. Procaps seeks (i) with respect to the alleged breaches, compensatory damages and (ii) with respect to the claim for unjust enrichment, (a) disgorgement of profits received by Patheon by using any confidential information of Procaps, (b) repayment for all payments made to Patheon pursuant to the collaboration agreement, and (c) payment for the value of any intellectual property associated with the collaboration agreement. The Company filed its answer to the request for arbitration with the International Court of Arbitration of the International Chamber of Commerce in June 2016. The arbitration hearing on the merits in this matter was held in March 2017 and final arguments were heard in May 2017. The Company has not included any accrual in the consolidated financial statements as of April 30, 2017 related to these matters as a result of its assessment that the likelihood of a material loss in connection with these matters is not probable. However, an adverse outcome in this matter could have a material adverse effect on the Company’s business, results of operations and financial condition. Oral Contraceptive Litigation A civil action is pending in the Commonwealth of Pennsylvania against the Company and one of its customers in connection with the recall of certain lots of allegedly defective products manufactured by the Company for the customer. The customer has given the Company notice of its intent to seek indemnification from the Company for all damages, costs and expenses, pursuant to the manufacturing services agreement between the customer and the Company. The action was filed in Court of Common Pleas of Philadelphia Country, in Philadelphia, Pennsylvania in November 2015 on behalf of 113 plaintiffs who were originally part of a putative class action commenced in state court in Georgia in October 2011 on behalf of 115 plaintiffs and removed by defendants to the United States District Court for the Northern District of Georgia ("Georgia District Court") under the Class Action Fairness Act ("CAFA"). Defendants opposed class certification and class certification was denied. The Georgia action was ordered to proceed as a two -plaintiff action in the Georgia District Court on behalf of the two named plaintiffs, whereupon plaintiffs' lawyers commenced a new action in the Court of Common Pleas in Philadelphia on behalf of the remaining 113 plaintiffs. The two -plaintiff action was dismissed by the Georgia District Court on October 28, 2016 on a motion for summary judgment brought by defendants. Defendants removed the action to the United States District Court for the Eastern District of Pennsylvania ("Pennsylvania District Court"). In September 2016, the Pennsylvania District Court remanded the action back to the Court of Common Pleas in Philadelphia. Defendants appealed the order of remand and, in February 2017, the United States Court of Appeals for the Third Circuit reversed and vacated the Pennsylvania District Court's remand order and remanded the matter to the Pennsylvania District Court for further proceedings. As the litigation is at an early stage, the Company is unable to estimate the potential damages for which the Company may be directly or indirectly liable. Italian Client Dispute In November 2015, the largest client of Patheon Italia S.p.A.’s (‘‘Patheon Italia’’), Ferentino, Italy facility filed a motion for injunctive relief in a Milan court under Article 700 of the Italian Civil Code. The client claims that remediation actions implemented by the Ferentino facility in response to an FDA inspection in May 2015, including, among other things, the use of a third party to certify all production batches for release, caused a significant slowdown in the quality control testing and batch release processes for the client’s product, thereby impairing the client’s ability to supply product in the amounts needed to fulfill the client's needs. The client sought an injunction ordering the Ferentino facility to (i) deliver products set forth in an October 6-7, 2015 release plan discussed by the parties; (ii) transfer products and documentation to the client to enable the client to perform the necessary quality control testing and release the products; and (iii) continue manufacture of the products at the capacity levels set forth in the supply agreement between the parties. The client further asked the court to impose a penalty of €0.2 million per day for every day that the Ferentino facility failed to comply with the order. On December 7, 2015, Patheon Italia filed a response to the motion, denying all the claims set forth in the client’s motion and asserting several defenses. In particular, Patheon Italia informed the court that the parties had in fact executed an amendment to the existing quality agreement agreeing to transfer the testing and release responsibilities to the client, such amendment was executed prior to the filing of the motion by the client and should have been disclosed to the court in the client’s motion. On December 10, 2015, the court held a hearing in this matter and on December 18, 2015, denied the client’s motion. The client has filed an appeal to the court's decision, which was heard on February 11, 2016. On February 29, 2016, the appeals court denied the client's appeal. The supply agreement with the client includes an arbitration provision and in its initial motion, the client indicated its intention to file an arbitration claim seeking money damages in this matter. This matter is in the early stages and the Company is unable to estimate the potential damages for which Patheon Italia may be liable if the client files an arbitration claim and prevails in such proceeding. Statements of cash flows non-cash investing and financing activities Six months ended April 30, 2017 2016 Non-cash financing activities: $ $ Assumption of earnout liability from the Partnership (1) — 36.0 Treasury stock purchases to satisfy certain tax withholdings (2) 0.1 — Increase in capital lease obligations 1.0 — (1) Refer to Note 9 for further information (2) Represents the tax payable held as of April 30, 2017 relating to a second quarter treasury stock purchase.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Apr. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On May 15, 2017, the Company and Thermo Fisher Scientific Inc. ("Thermo Fisher") and Thermo Fisher (CN) Luxembourg Sarl (the “Buyer”) entered into a Purchase Agreement pursuant to which the Buyer will commence a tender offer to all outstanding shares of the Company for $35.00 per share (the "Offer Consideration"). The transaction represents a purchase price of approximately $7.2 billion , which includes the assumption of approximately $2.0 billion of net debt. The closing of the tender offer (the “Closing”) will constitute an Exit Event under the MEIP and the LTIP and, accordingly, (i) all management units under the MEIP that are unvested as of the Closing will vest in full, (ii) the MEIP RSUs will settle in accordance with their terms based on the Offer Consideration; and (iii) all outstanding awards under the LTIP will become payable. All remaining unvested equity awards under the Company's Omnibus Incentive Plan will convert into an equity award of Thermo Fisher with the same value and substantially similar other terms as the existing Company equity award.

BASIS OF PRESENTATION AND SUM25

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation Patheon consists of three reportable segments: Drug Product Services ("DPS"), Pharmaceutical Development Services ("PDS"), and Drug Substance Services ("DSS"). Drug Product Services provides manufacturing and packaging for approved prescription, over-the-counter, and nutritional products. Pharmaceutical Development Services provides a wide spectrum of advanced formulation, production, and technical services from the early stages of a product's development to regulatory approval and beyond, as well as for new formulations of approved products for life cycle extension. Drug Substance Services provides development and manufacturing for the biologically active component of a pharmaceutical product from early development through commercial production. The accompanying unaudited consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). Operating results for the three and six months ended April 30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending October 31, 2017 ("fiscal 2017 "). These consolidated financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and therefore should be read in conjunction with the audited consolidated financial statements and notes for the fiscal year ended October 31, 2016 ("fiscal 2016 "). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect: the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and the reported amounts of revenue and expenses in the reporting period. Management believes that the estimates and assumptions used in preparing its consolidated financial statements are reasonable and prudent; however, actual results could differ from those estimates.
Segment information	Segment information U.S. GAAP requires segmentation based on an entity’s internal organization and reporting of revenue and operating income (loss) based upon internal accounting methods commonly referred to as the “management approach.” Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), or decision making group, in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company’s four operating segments are: North America Drug Product Services, or North America DPS, Europe Drug Product Services, or Europe DPS, Pharmaceutical Development Services, or PDS and Drug Substance Services, or DSS. The North America DPS and Europe DPS operating segments meet the aggregation criteria to be presented as one reportable segment referred to as DPS. As a result, the Company has determined it has three reportable segments: DPS, PDS, and DSS. Corporate is not an individually reportable segment because the quantitative thresholds have not been met and as such has been reported in Other.
Recently adopted and issued accounting pronouncements	Recently adopted accounting pronouncements Accounting Standards Update ("ASU") Description Date Adopted Improvements to Employee Share-Based Payment Accounting (ASU 2016-09) This update simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company early-adopted ASU 2016-09 during the second quarter of fiscal 2017, which had no effect on the Company's financial statements. February 1, 2017 Simplifying the Accounting for Measurement-Period Adjustment (ASU 2015-16) This update eliminated the requirement to an acquirer in a business combination to retrospectively adjust provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Instead, the update requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The impact will be dependent on future transactions. November 1, 2016 Simplifying the Presentation of Debt Issuance Costs (ASU 2015-03) The pronouncement requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with that of debt discounts. The pronouncement is being applied retrospectively and the Company's October 31, 2016 balance sheet has been adjusted. The April 30, 2017 and October 31, 2016 balance sheets were adjusted to decrease the deferred financing cost asset and decrease the long term debt liability by $45.2 million and $50.3 million, respectively. November 1, 2016 Recently issued accounting pronouncements Accounting Standards Update ("ASU") Description Expected Impact Effective Date Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (ASU 2017-07) This update requires that an employer disaggregate the service cost component from the other components of net periodic benefit cost. In addition, only the service cost component will be eligible for capitalization. The amendment is applied retrospectively with earlier application permitted. We are assessing the impact to the individual line items to the Statements of Operations. The Company does not expect there to be a material impact to net income. November 1, 2018 Simplifying the Test for Goodwill Impairment (ASU 2017-04) This update simplified the subsequent measurement of goodwill by eliminating Step 2 of the goodwill impairment test. Instead, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The amendment also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. The amendment is applied prospectively with earlier application permitted. We do not expect to have a material impact on the Company’s financial statements. November 1, 2020 Clarifying the Definition of a Business (ASU 2017-01) This update narrows the definition of outputs and aligns it with how outputs are described in Topic 606. The amendment also provides a more robust framework to use in determining when a set of assets and activities is a business. The amendment is applied prospectively with earlier application permitted. The impact on the consolidated financial statements from the adoption of this guidance is dependent on future business combinations. November 1, 2018 Revenue from Contracts with Customers and related standards (ASU's 2014-09, 2016-08, 2016-10, 2016-12, 2016-20) This update supersedes the existing revenue recognition guidance and provides a new framework for recognizing revenue. These updates identified practical expedients and clarified various aspects of the new revenue recognition standard outlined in Accounting Standards Update 2014-09. This standard may be adopted using either a retrospective or modified retrospective method. Early adoption is permitted. We are currently in the process of evaluating the impact of this standard. It is still too early in our process to determine the magnitude of the potential impact. However, based on our preliminary assessment, we believe the timing of revenue recognition for commercial and development contracts may differ from our current revenue recognition policies. The Company is determining the magnitude of this potential change. We plan to adopt the standard on November 1, 2018, and we have not yet selected a transition method. November 1, 2018 From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above or in our audited consolidated financial statements and notes for fiscal 2016 , believes these standards will not have a material impact on the Company’s results of operations, cash flows, or financial position. A more detailed listing of recently issued accounting pronouncements are included in our audited consolidated financial statements and notes for fiscal 2016 .

BUSINESS COMBINATIONS (Tables)

BUSINESS COMBINATIONS (Tables)	6 Months Ended
	Apr. 30, 2017
Business Combinations [Abstract]
Schedule of Preliminary Purchase Price Allocation	The preliminary purchase price allocation for the RCI Acquisition is as follows: $ Assets Inventories 9.4 Prepaid expenses and other 0.1 Capital assets 155.6 Total assets acquired 165.1 Liabilities Accounts payable and accrued liabilities 2.0 Deferred revenue 67.0 Deferred tax liabilities 59.4 Total liabilities assumed 128.4 Total net assets 36.7 Bargain purchase gain (26.4 ) Total purchase price 10.3
Schedule of Financial Results	The revenues and net income from continuing operations from the RCI Acquisition for the period from February 1, 2017 to April 30, 2017 included in the consolidated statement of operations are as follows: February 1, 2017 to April 30, 2017 $ Revenues 8.1 Net income from continuing operations (1) 25.9 (1) Net income from continuing operations includes the $ 26.4 million of the bargain purchase gain
Schedule of Unaudited Pro Forma Information	The following unaudited supplemental pro forma information presents the financial results as if the acquisition had occurred on November 1, 2015. The unaudited supplemental pro forma information does not purport to be indicative of what would have occurred had the acquisition been completed on November 1, 2015, nor is it indicative of any future results. Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Revenues 483.4 484.0 999.1 904.9 Net income from continuing operations 1.2 (6.0 ) 11.4 (258.8 ) (1) Net income from continuing operations for the six months ended April 30, 2016 includes $257.8 million of impairment expense related to Roche's strategic realignment of the facility. This is not part of the acquisition transaction and as such is not removed from the pro forma financial information.

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Apr. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Results of Discontinued Operations	The results of the above dispositions have been presented as discontinued operations, the results of which for the three and six months ended April 30, 2016 are as follows: Three months ended April 30, Six months ended April 30, 2016 2016 $ $ Revenues — 2.1 Cost of goods sold — 1.9 Gross profit — 0.2 Selling, general and administrative expenses — 0.4 Loss on disposals, net 0.9 2.8 Operating loss (0.9 ) (3.0 ) Foreign exchange income, net (0.1 ) (0.1 ) Loss before income taxes (0.8 ) (2.9 ) Provision for income taxes 0.2 0.2 Net loss (1.0 ) (3.1 )

SUPPLEMENTAL BALANCE SHEET IN28

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2017
Supplemental Balance Sheet Information [Abstract]
Schedule of Inventories	Inventories consisted of the following: April 30, 2017 October 31, 2016 $ $ Raw materials, packaging components and spare parts 228.7 192.1 Work-in-process 92.3 80.9 Finished goods 130.6 122.2 Balance, end of period 451.6 395.2
Schedule of Accounts Payable and Accrued Liabilities	Accounts payable and accrued liabilities consisted of the following: April 30, 2017 October 31, 2016 $ $ Trade payables 277.1 279.3 Interest payable 9.8 14.0 Accrued salaries and related expenses 78.8 81.8 Customer deposits 4.1 4.3 Repositioning 4.9 5.4 Other accruals 7.5 8.8 Balance, end of period 382.2 393.6
Schedule of Finite-Lived Intangible Assets Acquired	The following table summarizes gross carrying amounts, accumulated amortization, and accumulated impairments related to the Company's identifiable intangible assets as of April 30, 2017 : Definite-lived intangible assets Gross carrying value Accumulated amortization Net carrying value Weighted Average Useful Life (in Years) $ $ $ Favorable agreements 1.0 (1.0 ) — — Trade names 1.6 (0.9 ) 0.7 5.6 Developed technology 54.1 (19.4 ) 34.7 10.8 Trade secrets and patents 2.5 (0.4 ) 2.1 14.5 Customer relationships 248.8 (49.5 ) 199.3 14.2 Non-compete agreements 2.6 (2.2 ) 0.4 3.0 Subtotal 310.6 (73.4 ) 237.2 Foreign exchange (3.3 ) Balance, end of period 233.9
Schedule of Indefinite-Lived Intangible Assets Acquired	Indefinite-lived intangible assets Gross carrying value Accumulated impairment Net carrying value $ $ $ In-process research and development 2.2 (0.9 ) 1.3 Regulatory permits 0.2 — 0.2 Subtotal 2.4 (0.9 ) 1.5 Foreign exchange (0.2 ) Balance, end of period 1.3
Schedule of Goodwill	The following table summarizes the changes in the carrying amount of goodwill for the six months ended April 30, 2017 : Total $ Balance at October 31, 2016 (1) 281.6 Foreign currency translation adjustments (0.2 ) Balance at April 30, 2017 281.4 (1) The opening cumulative goodwill balance is reflective of historical impairment charges of the full value of goodwill.

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Apr. 30, 2017
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt in the accompanying consolidated balance sheets at April 30, 2017 and October 31, 2016 consists of the following: As of April 30, 2017 As of October 31, 2016 $ $ USD Term Loan at LIBOR with a floor of 1% plus 3.25% rate and maturity date of April 20, 2024 (the "Credit Agreement") 1,133.1 — Euro Term Loan at LIBOR with a floor of 1% plus 3.00% rate and maturity date of April 20, 2024 (the "Credit Agreement") 504.5 — USD Term Loan with a base rate plus 2.25% or LIBOR with a floor of 1% plus 3.25% rate and maturity date of March 10, 2021 (the "Credit Agreement") — 1,138.9 Euro Term Loan with a base rate plus 2.50% or LIBOR with a floor of 1% plus 3.50% rate and maturity date of March 10, 2021 (the "Credit Agreement") — 511.0 7.50% Senior Notes due February 1, 2022 (the "Notes") 450.0 450.0 Secured Revolving Facility balance at LIBOR plus 3.25% rate and maturity terms on a rolling basis 50.0 20.0 Government of Austria research and development loans with annual interest rates ranging from 1.56% to 2.00% and maturities through March 2020 2.7 3.5 Italian subsidized loan with annual interest rate of 0.5%, and maturity date of June 30, 2020 3.6 4.1 Italian bank loan with Euribor 6-month + 7.1% rate, and maturity date of June 30, 2020 0.7 0.7 Capital lease obligations 1.6 0.7 Total long-term debt outstanding 2,146.2 2,128.9 Less original issue discount, net of accumulated amortization of $7.1 million and $6.2 million, respectively (12.2 ) (9.9 ) Less deferred financing costs (45.2 ) (50.3 ) Less current portion (19.4 ) (19.5 ) Balance, end of the period 2,069.4 2,049.2
Schedule of Maximum Leverage Ratio	The following table discloses the maximum First Lien Leverage Ratios permitted under the Credit Agreement: Testing Period Ending Maximum Ratio April 30, 2014 through October 31, 2014 6.75 to 1.00 November 1, 2014 through October 31, 2015 6.50 to 1.00 November 1, 2015 through October 31, 2016 6.25 to 1.00 November 1, 2016 through October 31, 2017 6.00 to 1.00 November 1, 2017 and thereafter 5.75 to 1.00
Schedule of Redemption Prices	On and after February 1, 2017, the Company may redeem all or a portion of the Notes at the applicable redemption prices set forth below (expressed as percentages of principal amount redeemed), plus unpaid interest accruing on the principal amount redeemed to the Redemption Date: Year % 2017 105.625 2018 103.750 2019 101.875 2020 and thereafter 100.000

PENSION AND POST-RETIREMENT B30

PENSION AND POST-RETIREMENT BENEFITS (Tables)	6 Months Ended
	Apr. 30, 2017
Postemployment Benefits [Abstract]
Schedule of Net Periodic Benefit Cost	The components of net periodic benefit cost from continuing operations for the defined benefit plans and other benefit plans for the three and six months ended April 30, 2017 and 2016 were as follows: Three months ended April 30, 2017 2016 Defined benefit pension plans Other benefit plans Defined benefit pension plans Other benefit plans $ $ $ $ Service cost 0.6 — 0.4 — Interest cost 1.0 — 1.3 — Expected return on plan assets (1.0 ) — (1.2 ) — Amortization of actuarial loss 0.7 — 0.4 — Net periodic benefit costs 1.3 — 0.9 — Six months ended April 30, 2017 2016 Defined benefit Other benefit Defined benefit Other benefit $ $ $ $ Service cost 1.2 — 0.9 — Interest cost 2.0 0.1 2.6 0.1 Expected return on plan assets (2.0 ) — (2.5 ) — Amortization of actuarial loss 1.4 — 0.8 — Net periodic benefit costs 2.6 0.1 1.8 0.1

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	6 Months Ended
	Apr. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The details of the computation of basic and diluted earnings (loss) per ordinary share are as follows: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 Numerator (in millions): Income (loss) from continuing operations $ 27.6 $ 1.9 $ 55.9 $ (18.1 ) Loss from discontinued operations $ — $ (1.0 ) $ — $ (3.1 ) Denominator: Weighted-average number of shares of ordinary shares - basic 145,136,214 115,609,756 145,132,349 115,609,756 Effect of dilutive securities: Restricted stock units 1,092,951 — 1,116,435 — Stock options 37,963 — 27,567 — Weighted-average number of shares of ordinary shares - diluted 146,267,128 115,609,756 146,276,351 115,609,756 Earnings (loss) per ordinary share - basic: From continuing operations $ 0.19 $ 0.02 $ 0.39 $ (0.16 ) From discontinued operations $ — $ (0.01 ) $ — $ (0.03 ) Earnings (loss) per ordinary share - diluted: From continuing operations $ 0.19 $ 0.02 $ 0.38 $ (0.16 ) From discontinued operations $ — $ (0.01 ) $ — $ (0.03 )

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Based Compensation	A summary of equity based compensation expense recognized during the three and six months ended April 30, 2017 and 2016 is as follows: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Management Equity Incentive Plan (MEIP) 1.9 2.0 4.2 3.0 Restricted Stock Units 4.0 — 5.3 — Stock Options 1.1 — 1.5 — Stock Based Compensation Expense 7.0 2.0 11.0 3.0 A summary of Standard RSUs activity for the six months ended April 30, 2017 is as follows: Restricted Share Units Weighted Average Grant Date Fair Value $ Outstanding as of October 31, 2016 450,184 21.00 Granted 1,028,534 26.46 Vested (70,700 ) 21.00 Outstanding as of April 30, 2017 1,408,018 24.79 A summary of stock option activity for the six months ended April 30, 2017 is as follows: Stock Options Weighted Average Fair Value $ Outstanding as of October 31, 2016 1,021,584 8.29 Granted 726,166 10.18 Outstanding as of April 30, 2017 1,747,750 9.08
Schedule of Plan Activity	A summary of the MEIP activity for the six months ended April 30, 2017 is as follows: Class B Class C Class D Class E Total Weighted Average Fair Value Outstanding as of October 31, 2016 59,290 8,470 8,470 8,470 84,700 $ 687.27 Forfeited (288 ) (50 ) (50 ) (50 ) (438 ) $ 870.09 Outstanding as of April 30, 2017 59,002 8,420 8,420 8,420 84,262 $ 686.32
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The estimated weighted average fair value of stock options is $9.08 per option and was estimated using a Black-Scholes valuation model, using the following weighted average assumptions: Risk free interest rate 1.6 % Expected volatility 38.1 % Expected life of options (in years) 6.0 Dividend yield — % The Monte Carlo simulation model incorporated the following weighted average assumptions: Risk free interest rate 0.9 % Expected volatility 41.6 % Estimated years to exit event 2.98

FINANCIAL INSTRUMENTS, FAIR V33

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT(Tables)	6 Months Ended
	Apr. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value	The following table provides a summary of the financial assets and liabilities that are measured at fair value as of April 30, 2017 and October 31, 2016 : Fair value measurement at April 30, 2017 Fair value measurement at October 31, 2016 Assets measured at fair value Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total $ $ $ $ $ $ $ $ Available-for-sale securities 1.4 — — 1.4 1.4 — — 1.4 Held-for-trading securities — 1.5 — 1.5 — 1.4 — 1.4 Total assets 1.4 1.5 — 2.9 1.4 1.4 — 2.8 Fair value measurement at April 30, 2017 Fair value measurement at October 31, 2016 Liabilities measured at fair value Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total $ $ $ $ $ $ $ $ Foreign exchange forward contracts — 1.8 — 1.8 — 2.7 — 2.7 Earnout liability — — 37.9 37.9 — — 33.8 33.8 Total liabilities — 1.8 37.9 39.7 — 2.7 33.8 36.5 Level 1 - Based on quoted market prices in active markets. Level 2 - Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly. Level 3 - Unobservable inputs that are not corroborated by market data.
Schedule of Derivative Financial Instruments and Investments Classification on Consolidated Balance Sheet	The following table presents the fair value of the Company's financial instruments and their classifications on the consolidated balance sheets as of April 30, 2017 and October 31, 2016 : Assets as of April 30, 2017 Assets as of October 31, 2016 Balance sheet location Fair value Balance sheet location Fair value $ $ Available-for-sale securities Investments 1.4 Investments 1.4 Held-for-trade securities Investments 1.5 Investments 1.4 Total 2.9 2.8 Liabilities as of April 30, 2017 Liabilities as of October 31, 2016 Balance sheet location Fair value Balance sheet location Fair value $ $ Foreign exchange forward contracts Accounts payable and accrued liabilities 1.8 Accounts payable and accrued liabilities 2.7 Earnout liability Other long-term liabilities 37.9 Other long-term liabilities 33.8 Total 39.7 36.5
Schedule of Fair Values and Carrying Values of Long-term Debt	As of April 30, 2017 , the fair values and carrying values of the Company’s long-term debt, including the current portion of long-term debt, are categorized in the table below: Fair Value Level 1 Level 2 Level 3 Total Carrying Value $ $ $ $ $ Long-term debt, including current portion — 2,179.3 — 2,179.3 2,134.0 As of October 31, 2016 , the fair values and carrying values of the Company’s long-term debt, including the current portion of long-term debt, are categorized in the table below: Fair Value Level 1 Level 2 Level 3 Total Carrying Value $ $ $ $ $ Long-term debt, including current portion — 2,156.8 — 2,156.8 2,119.0
Schedule of Earnout Liability Activity	The earnout liability activity is summarized as follows for the six months ended April 30, 2017 : Total $ Balance at October 31, 2016 33.8 Change in fair value 4.1 Balance at April 30, 2017 37.9
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	The following table summarizes the foreign currency activity on the intercompany loans that are included as part of the net investment in certain foreign subsidiaries for the three and six months ended April 30, 2017 and 2016 since net investment hedge inception: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Foreign exchange gain for the period from long-term intercompany loan revaluation — 3.8 — 3.0 The following table summarizes the net investment hedge foreign exchange activity for the three and six months ended April 30, 2017 and 2016 since net investment hedge inception: Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Foreign exchange (loss) gain for the period from net investment hedge (4.6 ) (29.0 ) 4.0 (21.0 ) Release of ineffective portion of net investment hedge to consolidated statement of operations — 3.3 — 2.2 Net (loss) gain to other comprehensive income for the period related to net investment hedge (4.6 ) (25.7 ) 4.0 (18.8 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Results	Three months ended April 30, 2017 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 297.2 57.8 129.2 — (0.8 ) 483.4 Adjusted EBITDA 77.4 18.4 26.1 (27.5 ) (0.2 ) 94.2 Depreciation and amortization 15.4 1.9 16.1 0.9 34.3 Capital expenditures 19.5 1.7 11.6 7.4 40.2 Three months ended April 30, 2016 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 287.4 53.4 127.9 — (0.1 ) 468.6 Adjusted EBITDA 72.7 16.7 30.8 (22.2 ) 98.0 Depreciation and amortization 14.9 1.3 10.2 0.6 27.0 Capital expenditures 11.7 5.9 9.0 4.3 30.9 Six months ended April 30, 2017 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 572.4 110.1 259.1 — (0.8 ) 940.8 Adjusted EBITDA 138.8 34.7 58.1 (54.7 ) (0.2 ) 176.7 Depreciation and amortization 30.7 3.7 25.8 1.7 61.9 Capital expenditures 56.4 3.1 29.5 10.2 99.2 Six months ended April 30, 2016 DPS PDS DSS Other Intersegment Eliminations Total $ $ $ $ $ $ Revenues 545.9 101.9 226.8 — (0.1 ) 874.5 Adjusted EBITDA 127.8 30.5 45.6 (46.9 ) 157.0 Depreciation and amortization 29.7 2.5 20.1 1.2 53.5 Capital expenditures 56.7 15.6 16.3 6.5 95.1
Reconciliation of Adjusted EBITDA	Below is a reconciliation of Adjusted EBITDA to its most comparable U.S. GAAP measure. Three months ended April 30, Six months ended April 30, 2017 2016 2017 2016 $ $ $ $ Total Adjusted EBITDA 94.2 98.0 176.7 157.0 Depreciation and amortization (34.3 ) (27.0 ) (61.9 ) (53.5 ) Repositioning expenses (1) (2.2 ) (1.3 ) (3.5 ) (2.5 ) Acquisition and integration costs (8.1 ) (7.6 ) (11.6 ) (10.2 ) Interest expense, net (30.8 ) (42.6 ) (59.0 ) (86.4 ) Benefit from (provision for) income taxes 1.5 (0.7 ) 22.8 — Refinancing expenses (6.3 ) — (6.3 ) — Operational initiatives related consulting costs (1.4 ) (1.9 ) (2.5 ) (3.3 ) IPO costs — (0.4 ) — (0.8 ) Acquisition related litigation expenses (3.7 ) (0.9 ) (6.0 ) (1.9 ) Stock based compensation expense (7.0 ) (2.0 ) (11.0 ) (3.0 ) FDA remediation costs — (10.1 ) — (18.5 ) Environmental remediation costs — — (3.7 ) — Bargain purchase gain 26.4 — 26.4 — Other (0.7 ) (1.6 ) (4.5 ) 5.0 Net income (loss) from continuing operations 27.6 1.9 55.9 (18.1 ) (1) Repositioning expenses for the three and six months ended April 30, 2017 includes $0.4 million and $1.1 million of inventory reserves related to the Swindon wind down recorded in cost of goods sold.
Schedule of Revenue, Capital Assets and Goodwill, by Country	As illustrated in the table below, revenues are attributed to countries based on the location of the customer's billing address, capital assets are attributed to the country in which they are located and goodwill is attributed to the country in which the entity to which the goodwill pertains is located: Three months ended April 30, 2017 Canada US* Europe Other** Total $ $ $ $ $ Revenues 4.2 282.8 167.9 28.5 483.4 * Includes Puerto Rico ** Primarily includes Japan Three months ended April 30, 2016 Canada US* Europe Other** Total $ $ $ $ $ Revenues 5.1 317.6 124.8 21.1 468.6 * Includes Puerto Rico ** Primarily includes Japan As of and for the six months ended April 30, 2017 Canada US* Europe Other** Total $ $ $ $ $ Revenues 11.2 564.7 320.7 44.2 940.8 Capital Assets 100.1 687.6 367.5 14.1 1,169.3 Goodwill 2.5 269.4 7.4 2.1 281.4 * Includes Puerto Rico ** Other revenues primarily include Japan As of and for the six months ended April 30, 2016 Canada US* Europe Other** Total $ $ $ $ $ Revenues 12.4 589.4 236.7 36.0 874.5 Capital Assets 100.8 487.3 341.6 16.1 945.8 Goodwill 2.8 269.4 7.7 2.2 282.1 * Includes Puerto Rico ** Other revenues primarily include Japan

REPOSITIONING EXPENSES (Tables)

REPOSITIONING EXPENSES (Tables)	6 Months Ended
	Apr. 30, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following is a summary of these expenses and other charges associated with operational improvements as of and for the three and six months ended April 30, 2017 and 2016 : As of and for the three months ended April 30, 2017 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at January 31, 2017 4.6 Employee-related expenses 1.7 — — 0.1 1.8 Repositioning expenses paid (1.6 ) Foreign exchange 0.1 Total repositioning liability at April 30, 2017 4.9 As of and for the three months ended April 30, 2016 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at January 31, 2016 4.9 Employee-related expenses 1.6 — — — 1.6 Consulting, professional and project management costs (0.3 ) — — — (0.3 ) Total expenses 1.3 — — — 1.3 Repositioning expenses paid (3.1 ) Foreign exchange 0.3 Total repositioning liability at April 30, 2016 3.4 As of and for the six months ended April 30, 2017 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at October 31, 2016 5.4 Employee-related expenses 1.9 — — 0.5 2.4 Repositioning expenses paid (3.1 ) Foreign exchange 0.2 Total repositioning liability at April 30, 2017 4.9 The balance of repositioning liabilities as of April 30, 2017 was recorded in accounts payable and accrued liabilities on the consolidated balance sheet. The Company does not have any long-term repositioning liabilities as of April 30, 2017 . As of and for the six months ended April 30, 2016 DPS PDS DSS Other Total $ $ $ $ $ Total repositioning liability at October 31, 2015 22.9 Employee-related expenses 2.8 — — — 2.8 Consulting, professional and project management costs (0.3 ) — — — (0.3 ) Total expenses 2.5 — — — 2.5 Repositioning expenses paid (21.8 ) Foreign exchange (0.2 ) Total repositioning liability at April 30, 2016 3.4

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	6 Months Ended
	Apr. 30, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Values as of Equity Method Investment Values April 30, 2017 October 31, 2016 $ $ Banner Life Sciences 2.5 2.9 Percivia 5.7 5.7 Chemiepark 0.1 0.1 Total 8.3 8.7 The expenses relating to these services are charged to BLS and the related accounts receivable outstanding in relation to these services are shown in the tables below. We performed production services for BLS in the first quarter of fiscal 2016 before BLS sold their commercial business to a third party. Three months ended April 30, Six months ended April 30, Revenues/Expenses 2017 2016 2017 2016 $ $ $ $ JLL Partners Expenses 0.1 0.1 0.1 0.2 DSM Revenues 0.1 0.8 0.3 0.9 DSM Expenses 1.9 2.5 5.1 5.2 Banner Life Sciences Revenues 0.7 1.4 0.7 7.9 Balances as of Accounts Receivable/Payable Balances April 30, 2017 October 31, 2016 $ $ JLL Partners Accounts Payable 0.1 — DSM Accounts Receivable 0.1 0.4 DSM Accounts Payable 1.7 0.2 Banner Life Sciences Accounts Receivable 1.2 1.1 Three months ended April 30, Six months ended April 30, Equity Method (Loss)/Gain 2017 2016 2017 2016 $ $ $ $ Banner Life Sciences (0.2 ) (0.5 ) (0.3 ) 1.3 Percivia — 0.1 — 0.2 Total (0.2 ) (0.4 ) (0.3 ) 1.5

OTHER INFORMATION (Tables)

OTHER INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2017
Other Information [Abstract]
Statements of Cash Flows Non-cash Investing and Financing Activities	Statements of cash flows non-cash investing and financing activities Six months ended April 30, 2017 2016 Non-cash financing activities: $ $ Assumption of earnout liability from the Partnership (1) — 36.0 Treasury stock purchases to satisfy certain tax withholdings (2) 0.1 — Increase in capital lease obligations 1.0 — (1) Refer to Note 9 for further information (2) Represents the tax payable held as of April 30, 2017 relating to a second quarter treasury stock purchase.

THE COMPANY - Narrative (Detail

THE COMPANY - Narrative (Details) $ / shares in Units, $ in Millions	Jul. 26, 2016USD ($)	Jul. 21, 2016USD ($)shares	Apr. 30, 2017vote€ / sharesshares	Oct. 31, 2016€ / shares	Jul. 21, 2016€ / sharesshares	Jul. 21, 2016$ / sharesshares	Dec. 24, 2013
Other Ownership Interests [Line Items]
Proceeds from partner contribution | $		$ 1.2
Common stock, shares outstanding (in shares)			145,136,214		115,609,756	115,609,756
Common stock, par value (in euros per share) | € / shares			€ 0.01	€ 0.01	€ 0.01
Proceeds from IPO | $	$ 584.8
Number of voting rights | vote			1
JLL Patheon Co-Investment Fund L.P.
Other Ownership Interests [Line Items]
Ownership percentage by parent	38.00%						51.00%
Koninklijke DSM
Other Ownership Interests [Line Items]
Ownership percentage by parent	34.00%						49.00%
JLL/Delta Patheon Holdings
Other Ownership Interests [Line Items]
Ownership percentage by parent	4.00%
IPO
Other Ownership Interests [Line Items]
Issuance of ordinary shares (in shares)		29,464,286
IPO price per shares (in USD per share) | $ / shares						$ 21
Rights to purchase addition ordinary shares (in shares)		4,464,286
Total number of ordinary shares sold in connection with IPO (in shares)		34,226,191
Percentage of voting stock publicly owned	24.00%
IPO | Koninklijke DSM
Other Ownership Interests [Line Items]
Issuance of ordinary shares (in shares)		4,761,905

BASIS OF PRESENTATION AND SUM39

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) $ in Millions	6 Months Ended
	Apr. 30, 2017USD ($)segment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments	3
Number of operating segments	4
DPS reportable segment	1
Deferred finance costs | $	$ 45.2
Accounting Standards Update 2015-03 | Long-term Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs | $	$ (50.3)

BUSINESS COMBINATIONS - Narrati

BUSINESS COMBINATIONS - Narrative (Details) - Roche Carolina Inc. $ in Millions	Feb. 01, 2017USD ($)
Business Acquisition [Line Items]
Upfront payment to acquire stock of RCI	$ 1
Consideration transferred	$ 9.3

DISCONTINUED OPERATIONS - Narra

DISCONTINUED OPERATIONS - Narrative (Details) - Disposed of by sale € in Millions, $ in Millions	Jul. 31, 2015USD ($)	May 12, 2015USD ($)	Apr. 30, 2016EUR (€)	Apr. 30, 2016USD ($)	Aug. 31, 2015EUR (€)	Jul. 31, 2015EUR (€)
Banner Pharmacaps
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price		$ 36.4
Gain on disposals		$ 2.6
Biosolutions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price | €						€ 0.3
Gain on disposals	$ (24)
DPx Fine Chemicals
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price | €					€ 179
Gain on disposals				$ 107
Proceeds from working capital | €			€ 3

BUSINESS COMBINATIONS - Schedul

BUSINESS COMBINATIONS - Schedule of Preliminary Purchase Price Allocations (Details) - USD ($) $ in Millions	Feb. 01, 2017	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Mar. 31, 2015
Liabilities
Gain on bargain purchase		$ (26.4)	$ 0	$ (26.4)	$ 0
Roche Carolina Inc.
Assets
Inventories	$ 9.4
Prepaid expenses and other	0.1
Capital assets	155.6
Total assets acquired	165.1
Liabilities
Accounts payable and accrued liabilities	2
Deferred revenue	67
Deferred tax liabilities	59.4
Total liabilities assumed	128.4
Total net assets	36.7
Gain on bargain purchase	$ (26.4)
Total purchase price						$ 10.3

DISCONTINUED OPERATIONS - Sched

DISCONTINUED OPERATIONS - Schedule of Dispositions (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss	$ 0	$ (1)	$ 0	$ (3.1)
DPx Fine Chemicals | Disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		0		2.1
Cost of goods sold		0		1.9
Gross profit		0		0.2
Selling, general and administrative expenses		0		0.4
Loss on disposals, net		0.9		2.8
Operating loss		(0.9)		(3)
Foreign exchange income, net		(0.1)		(0.1)
Loss before income taxes		(0.8)		(2.9)
Provision for income taxes		0.2		0.2
Net loss		$ (1)		$ (3.1)

BUSINESS COMBINATIONS - Sched44

BUSINESS COMBINATIONS - Schedule of Financial Results (Details) - USD ($) $ in Millions	Feb. 01, 2017	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Business Acquisition [Line Items]
Bargain purchase gain		$ (26.4)	$ 0	$ (26.4)	$ 0
Roche Carolina Inc.
Business Acquisition [Line Items]
Revenues		8.1
Net income from continuing operations		$ 25.9
Bargain purchase gain	$ (26.4)

BUSINESS COMBINATIONS - Sched45

BUSINESS COMBINATIONS - Schedule of Unaudited Pro Forma Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
DPP Acquisition
Business Acquisition [Line Items]
Revenues	$ 483.4	$ 484	$ 999.1	$ 904.9
Net income from continuing operations	1.2	$ (6)	$ 11.4	(258.8)
Roche Carolina Inc.
Business Acquisition [Line Items]
Revenues	8.1
Net income from continuing operations	$ 25.9
Impairment expense related to Roche's strategic realignment				$ 257.8

SUPPLEMENTAL BALANCE SHEET IN46

SUPPLEMENTAL BALANCE SHEET INFORMATION - Inventories (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Supplemental Balance Sheet Information [Abstract]
Raw materials, packaging components and spare parts	$ 228.7	$ 192.1
Work-in-process	92.3	80.9
Finished goods	130.6	122.2
Balance, end of period	$ 451.6	$ 395.2

SUPPLEMENTAL BALANCE SHEET IN47

SUPPLEMENTAL BALANCE SHEET INFORMATION - Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Supplemental Balance Sheet Information [Abstract]
Trade payables	$ 277.1	$ 279.3
Interest payable	9.8	14
Accrued salaries and related expenses	78.8	81.8
Customer deposits	4.1	4.3
Repositioning	4.9	5.4
Other accruals	7.5	8.8
Balance, end of period	$ 382.2	$ 393.6

SUPPLEMENTAL BALANCE SHEET IN48

SUPPLEMENTAL BALANCE SHEET INFORMATION - Finite-Lived Intangible Assets Acquired (Details) $ in Millions	6 Months Ended
	Apr. 30, 2017USD ($)
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 310.6
Accumulated amortization	(73.4)
Net carrying value	237.2
Foreign exchange	(3.3)
Balance, end of period	233.9
Favorable agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	1
Accumulated amortization	(1)
Net carrying value	$ 0
Weighted Average Useful Life (in Years)	0 years
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 1.6
Accumulated amortization	(0.9)
Net carrying value	$ 0.7
Weighted Average Useful Life (in Years)	5 years 7 months 6 days
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 54.1
Accumulated amortization	(19.4)
Net carrying value	$ 34.7
Weighted Average Useful Life (in Years)	10 years 9 months 18 days
Trade secrets and patents
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 2.5
Accumulated amortization	(0.4)
Net carrying value	$ 2.1
Weighted Average Useful Life (in Years)	14 years 6 months
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 248.8
Accumulated amortization	(49.5)
Net carrying value	$ 199.3
Weighted Average Useful Life (in Years)	14 years 2 months 12 days
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 2.6
Accumulated amortization	(2.2)
Net carrying value	$ 0.4
Weighted Average Useful Life (in Years)	3 years

SUPPLEMENTAL BALANCE SHEET IN49

SUPPLEMENTAL BALANCE SHEET INFORMATION - Indefinite-Lived Intangible Assets (Details) $ in Millions	6 Months Ended
	Apr. 30, 2017USD ($)
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value	$ 2.4
Accumulated impairment	(0.9)
Net carrying value	1.5
Foreign exchange	(0.2)
Balance, end of period	1.3
In-process research and development
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value	2.2
Accumulated impairment	(0.9)
Net carrying value	1.3
Regulatory permits
Indefinite-lived Intangible Assets [Line Items]
Gross carrying value	0.2
Accumulated impairment	0
Net carrying value	$ 0.2

SUPPLEMENTAL BALANCE SHEET IN50

SUPPLEMENTAL BALANCE SHEET INFORMATION - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2016	Apr. 30, 2017	Jan. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Net carrying value		$ 1.5
Gross carrying value		2.4
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Net carrying value		1.3
Gross carrying value		$ 2.2
In-process research and development | BLS | Spinoff
Finite-Lived Intangible Assets [Line Items]
Net carrying value			$ 3.6
Gross carrying value			$ 7.9
Impairment losses	$ 4.3

SUPPLEMENTAL BALANCE SHEET IN51

SUPPLEMENTAL BALANCE SHEET INFORMATION - Goodwill (Details) $ in Millions	6 Months Ended
	Apr. 30, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 281.6
Foreign currency translation adjustments	(0.2)
Goodwill, end of period	$ 281.4

LONG-TERM DEBT - Schedule of Lo

LONG-TERM DEBT - Schedule of Long-term Debt in Accompanying balance Sheet (Details) - USD ($) $ in Millions	Apr. 20, 2017	Apr. 30, 2017	Jul. 31, 2013	Oct. 31, 2016	Oct. 31, 2015	Feb. 28, 2014
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 2,146.2		$ 2,128.9
Less original issue discount, net of accumulated amortization of $7.1 million and $6.2 million, respectively		(12.2)		(9.9)
Less deferred financing costs		(45.2)		(50.3)
Less current portion		(19.4)		(19.5)
Balance, end of the period		2,069.4		2,049.2
Accumulated amortization		7.1			$ 6.2
Domestic credit agreement | USD Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 1,133.1		0
Domestic credit agreement | USD Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.25%
Variable interest rate floor (as percent)		1.00%
Domestic credit agreement | USD term loan due March 2021
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 0		1,138.9
Domestic credit agreement | USD term loan due March 2021 | Base rate
Debt Instrument [Line Items]
Basis spread (as percent)		2.25%
Domestic credit agreement | USD term loan due March 2021 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.25%
Variable interest rate floor (as percent)		1.00%
Foreign credit agreement | Euro Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 504.5		0
Foreign credit agreement | Euro Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.00%
Variable interest rate floor (as percent)		1.00%
Foreign credit agreement | Euro term loan due March 2021
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 0		511
Foreign credit agreement | Euro term loan due March 2021 | Base rate
Debt Instrument [Line Items]
Basis spread (as percent)		2.50%
Foreign credit agreement | Euro term loan due March 2021 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.50%
Variable interest rate floor (as percent)		1.00%
Senior notes | 7.50% senior notes due February 2022
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 450		450
Stated rate (as percent)		7.50%				7.50%
Loan | Government of Austria research and development loans due March 2020
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 2.7		3.5
Loan | Italian subsidized loan due June 2020
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 3.6		4.1
Stated rate (as percent)		0.50%	0.50%
Loan | Italian bank loan due June 2020
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 0.7		0.7
Loan | Italian bank loan due June 2020 | Euribor rate
Debt Instrument [Line Items]
Basis spread (as percent)		7.10%	7.10%
Capital lease obligations
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 1.6		0.7
Minimum | Government of Austria research and development loans due March 2020
Debt Instrument [Line Items]
Stated rate (as percent)		1.56%
Maximum | Government of Austria research and development loans due March 2020
Debt Instrument [Line Items]
Stated rate (as percent)		2.00%
Secured revolving credit facility | Seller financing, non-Interest Bearing Loan Due May 2016
Debt Instrument [Line Items]
Total long-term debt outstanding		$ 50		$ 20
Basis spread (as percent)		3.25%
Secured revolving credit facility | Domestic credit agreement | USD Term Loan Due April 20, 2024 | Base rate
Debt Instrument [Line Items]
Basis spread (as percent)	2.25%
Secured revolving credit facility | Domestic credit agreement | USD Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)	3.25%

LONG-TERM DEBT - 2017 Term Loan

LONG-TERM DEBT - 2017 Term Loans and Revolving Line (Details)	Apr. 20, 2017USD ($)	Apr. 30, 2017USD ($)	Apr. 20, 2017EUR (€)	Apr. 20, 2017USD ($)
Line of credit
Debt Instrument [Line Items]
Maximum percentage of consolidated total assets (as percent)	3.00%
Additional threshold amount for dividend distribution	$ 65,000,000
Line of credit | Secured term loan
Debt Instrument [Line Items]
Prepayment amount from net cash proceeds of certain asset sales including insurance and condemnation proceeds, percentage	100.00%
Prepayment amount from net cash proceeds of issuance of debt obligations, percentage	100.00%
Prepayment amount from excess cash flows, value		$ 0
Line of credit | Secured term loan | First Lien Leverage Ratio Greater than 4.00 to 1.00
Debt Instrument [Line Items]
Leverage ratio (as percent)			4	4
Prepayment amount of excess cash flows, percentage	50.00%
Line of credit | Secured term loan | First Lien Leverage Ratio Less Than or Equal to 4.00 to 1.00 But Greater Than 3.50 to 1.00
Debt Instrument [Line Items]
Prepayment amount of excess cash flows, percentage	25.00%
Line of credit | Secured term loan | First Lien Leverage Ratio Less Than or Equal to 4.00 to 1.00 But Greater Than 3.50 to 1.00 | Minimum
Debt Instrument [Line Items]
Leverage ratio (as percent)			3.50	3.50
Line of credit | Secured term loan | First Lien Leverage Ratio Less Than or Equal to 4.00 to 1.00 But Greater Than 3.50 to 1.00 | Maximum
Debt Instrument [Line Items]
Leverage ratio (as percent)			4	4
Line of credit | Secured term loan | First Lien Leverage Ratio of Less Than or Equal to 3.50 to 1.00
Debt Instrument [Line Items]
Leverage ratio (as percent)			3.50	3.50
Prepayment amount of excess cash flows, percentage	0.00%
Line of credit | Secured revolving credit facility
Debt Instrument [Line Items]
Number of business days following deadline to be in compliance with First Lien Leverage Ratio	11 days
Line of credit | Secured revolving credit facility | Secured Revolving Facility Due April 20, 2024
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage (as percent)	0.50%
Minimum borrowing amount to maintain First Lien Leverage Ratio, percentage		25.00%	25.00%	25.00%
Minimum borrowing amount to maintain First Lien Leverage Ratio		$ 62,500,000		$ 62,500,000
Line of credit | Secured revolving credit facility | Secured Revolving Facility Due April 20, 2024 | FIrst Lien Leverage Ratio is less than or equal to 3.00 to 1.00
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage (as percent)	0.375%
Leverage ratio (as percent)			3	3
Domestic credit agreement | USD Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.25%
Variable interest rate floor (as percent)		1.00%
Domestic credit agreement | Secured term loan
Debt Instrument [Line Items]
Amount of borrowings outstanding		$ 50,000,000
Domestic credit agreement | Secured term loan | USD Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Amount of debt issued				$ 1,133,000,000
Domestic credit agreement | Secured term loan | USD Term Loan Due April 20, 2024 | Base rate
Debt Instrument [Line Items]
Basis spread (as percent)	2.25%
Domestic credit agreement | Secured term loan | USD Term Loan Due April 20, 2024 | Base rate | Minimum
Debt Instrument [Line Items]
Basis spread (as percent)	2.00%
Domestic credit agreement | Secured term loan | USD Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)	3.25%
Domestic credit agreement | Secured term loan | USD Term Loan Due April 20, 2024 | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread (as percent)	3.00%
Variable interest rate floor (as percent)	1.00%
Domestic credit agreement | Secured revolving credit facility | USD Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Amount of debt issued				250,000,000
Domestic credit agreement | Secured revolving credit facility | USD Term Loan Due April 20, 2024 | Base rate
Debt Instrument [Line Items]
Basis spread (as percent)	2.25%
Domestic credit agreement | Secured revolving credit facility | USD Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)	3.25%
Domestic credit agreement | Secured revolving credit facility | USD Term Loan Due To Terminate on March 2019
Debt Instrument [Line Items]
Amount of debt issued				87,100,000
Domestic credit agreement | Letter of credit | USD Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Amount of debt issued				75,000,000
Foreign credit agreement | Euro Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)		3.00%
Variable interest rate floor (as percent)		1.00%
Foreign credit agreement | Secured term loan | Euro Term Loan Due April 20, 2024
Debt Instrument [Line Items]
Amount of debt issued			€ 463,100,000	$ 496,300,000
Foreign credit agreement | Secured term loan | Euro Term Loan Due April 20, 2024 | LIBOR
Debt Instrument [Line Items]
Basis spread (as percent)	3.00%
Foreign credit agreement | Secured term loan | Euro Term Loan Due April 20, 2024 | LIBOR | Minimum
Debt Instrument [Line Items]
Variable interest rate floor (as percent)	1.00%

LONG-TERM DEBT - Schedule of Ma

LONG-TERM DEBT - Schedule of Maximum Leverage Ratios (Details) - Line of credit - Secured revolving credit facility - Secured revolving facility due March 2019	Mar. 11, 2014
April 30, 2014 through October 31, 2014
Line of Credit Facility [Line Items]
Maximum leverage ratio (as percent)	6.75
November 1, 2014 through October 31, 2015
Line of Credit Facility [Line Items]
Maximum leverage ratio (as percent)	6.50
November 1, 2015 through October 31, 2016
Line of Credit Facility [Line Items]
Maximum leverage ratio (as percent)	6.25
November 1, 2016 through October 31, 2017
Line of Credit Facility [Line Items]
Maximum leverage ratio (as percent)	6
November 1, 2017 and thereafter
Line of Credit Facility [Line Items]
Maximum leverage ratio (as percent)	5.75

LONG-TERM DEBT - 2014 Senior Un

LONG-TERM DEBT - 2014 Senior Unsecured Notes (Details) - Senior notes - 7.50% senior notes due February 2022 - USD ($)	Apr. 30, 2017	Feb. 28, 2014
Debt Instrument [Line Items]
Amount of debt issued		$ 450,000,000
Stated rate (as percent)	7.50%	7.50%

LONG-TERM DEBT - Schedule of Re

LONG-TERM DEBT - Schedule of Redemption Rates (Details) - Senior notes - 7.50% senior notes due February 2022	1 Months Ended
	Feb. 28, 2014
2,017
Debt Instrument [Line Items]
Redemption price (as percent)	105.625%
2,018
Debt Instrument [Line Items]
Redemption price (as percent)	103.75%
2,019
Debt Instrument [Line Items]
Redemption price (as percent)	101.875%
2020 and thereafter
Debt Instrument [Line Items]
Redemption price (as percent)	100.00%

LONG-TERM DEBT - Other Financin

LONG-TERM DEBT - Other Financing Arrangements (Details) € in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Apr. 30, 2017USD ($)	Apr. 30, 2016EUR (€)	Jul. 31, 2013EUR (€)paymentdebt_instrument	Apr. 30, 2017USD ($)	Apr. 30, 2016USD ($)	Oct. 31, 2016USD ($)	Aug. 31, 2015USD ($)
Debt Instrument [Line Items]
Proceeds from long-term debt				$ 30	$ 0.7
Total long-term debt outstanding	$ 2,146.2			$ 2,146.2		$ 2,128.9
Investment in Facility
Debt Instrument [Line Items]
Long-term investment commitment, minimum amount							$ 47
Loan
Debt Instrument [Line Items]
Number of incremental debt instruments | debt_instrument			2
Loan | Italian subsidized loan due June 2020
Debt Instrument [Line Items]
Amount of debt issued | €			€ 6
Proceeds from long-term debt | €		€ 0.6	€ 5.4
Stated rate (as percent)	0.50%		0.50%	0.50%
Total long-term debt outstanding	$ 3.6			$ 3.6		4.1
Loan | Italian bank loan due June 2020
Debt Instrument [Line Items]
Amount of debt issued | €			€ 0.7
Proceeds from long-term debt | €		€ 0.1	€ 0.6
Number of semi-annual installments | payment			6
Total long-term debt outstanding	$ 0.7			0.7		0.7
Loan | Italian bank loan due June 2020 | Euribor rate
Debt Instrument [Line Items]
Basis spread (as percent)	7.10%		7.10%
Loan | Government of Austria research and development loans due March 2020
Debt Instrument [Line Items]
Total long-term debt outstanding	$ 2.7			$ 2.7		$ 3.5
Other Obligations
Debt Instrument [Line Items]
Percentage of property tax payment due (as percent)							50.00%

PENSION AND POST-RETIREMENT B58

PENSION AND POST-RETIREMENT BENEFITS - Schedule of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Defined benefit pension plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0.6	$ 0.4	$ 1.2	$ 0.9
Interest cost	1	1.3	2	2.6
Expected return on plan assets	(1)	(1.2)	(2)	(2.5)
Amortization of actuarial loss	0.7	0.4	1.4	0.8
Net periodic benefit costs	1.3	0.9	2.6	1.8
Other benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost	0	0	0.1	0.1
Expected return on plan assets	0	0	0	0
Amortization of actuarial loss	0	0	0	0
Net periodic benefit costs	$ 0	$ 0	$ 0.1	$ 0.1

PENSION AND POST-RETIREMENT B59

PENSION AND POST-RETIREMENT BENEFITS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Oct. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Anticipated contributions required under the defined benefit pension plans and other benefit plans			$ 3.9
Contributions made under the defined benefit pension plans and other benefit plans					$ 5.2
Employee future benefit expense	$ 2.2	$ 1.6	4.5	$ 3.3
Italy
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation arrangement employer contribution			3.9		$ 3.4
Deferred compensation arrangement employer contribution related expenses	$ 0.9	$ 0.7	$ 1.8	$ 1.4

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Income (loss) from continuing operations	$ 27.6	$ 1.9	$ 55.9	$ (18.1)
Loss from discontinued operations	$ 0	$ (1)	$ 0	$ (3.1)
Weighted-average number of shares of ordinary shares - basic (in shares)	145,136,214	115,609,756	145,132,349	115,609,756
Effect of dilutive securities:
Weighted-average number of shares of ordinary shares - diluted (in shares)	146,267,128	115,609,756	146,276,351	115,609,756
Earnings (loss) per ordinary share - basic:
From continuing operations (in USD per share)	$ 0.19	$ 0.02	$ 0.39	$ (0.16)
From discontinued operations (in USD per share)	0	(0.01)	0	(0.03)
Earnings (loss) per ordinary share - diluted:
From continuing operations (in USD per share)	0.19	0.02	0.38	(0.16)
From discontinued operations (in USD per share)	$ 0	$ (0.01)	$ 0	$ (0.03)
Restricted Stock Units
Effect of dilutive securities:
Dilutive securities (in shares)	1,092,951	0	1,116,435	0
Stock Options
Effect of dilutive securities:
Dilutive securities (in shares)	37,963	0	27,567	0

STOCK BASED COMPENSATION - Sche

STOCK BASED COMPENSATION - Schedule of Share Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation Expense	$ 7	$ 2	$ 11	$ 3
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation Expense	4	0	5.3	0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation Expense	1.1	$ 0	1.5	$ 0
Management Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation Expense	1.9		$ 4.2
Management Equity Incentive Plan | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Based Compensation Expense	$ 1

STOCK BASED COMPENSATION - Mana

STOCK BASED COMPENSATION - Management Equity Incentive Plan (MEIP) (Details) $ / shares in Units, $ in Millions	Dec. 08, 2016USD ($)$ / sharesshares	Apr. 30, 2017USD ($)$ / sharesshares	Apr. 30, 2016USD ($)	Apr. 30, 2017USD ($)tranche$ / sharesshares	Apr. 30, 2016USD ($)	Oct. 31, 2016shares	Jul. 26, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 7	$ 2	$ 11	$ 3
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted share units under the omnibus Plan (in shares) | shares		1,408,018		1,408,018		450,184
Estimated fair value of MEIP RSU's (in USD per share) | $ / shares				$ 26.46
Stock-based compensation expense		$ 4	0	$ 5.3	0
IPO | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in USD per share) | $ / shares							$ 24.79
Management Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of valuation tranches | tranche				5
Stock-based compensation expense		$ 1.9		$ 4.2
Management Equity Incentive Plan | Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares distributed to be held for MEIP participants (in shares) | shares							6,106,540
Stock-based compensation expense			$ 2		$ 3
Management Equity Incentive Plan | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				5 years
Restricted share units under the omnibus Plan (in shares) | shares	196,485						3,388,481
Share price target (in USD per share) | $ / shares		$ 48.47		$ 48.47
Estimated fair value of MEIP RSU's (in USD per share) | $ / shares	$ 13.87	$ 8.41
Stock-based compensation expense		$ 1
Compensation costs not yet recognized	$ 1.7
Stock-based compensation expense reversed		$ 0.3
Management Equity Incentive Plan | IPO | Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in USD per share) | $ / shares							$ 21
Management Equity Incentive Plan | Class B
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold percentage of ownership of equity securities for exit event (less than)				20.00%
Percentage of excess capital contributions received to trigger an Exit Event		250.00%		250.00%
Compensation costs not yet recognized		$ 31.9		$ 31.9
Compensation costs not yet recognized, to be recognized before Exit Event				$ 3.4
Management Equity Incentive Plan | Class B | Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of service-based units				71.40%
Vesting period				4 years
Stock-based compensation expense		1.4		$ 2.9
Compensation costs not yet recognized		8.5		8.5
Management Equity Incentive Plan | Class B | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		0.2		$ 0.4
Management Equity Incentive Plan | Class C
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class C, class D, and class E vesting thresholds				200.00%
Management Equity Incentive Plan | Class D
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class C, class D, and class E vesting thresholds				250.00%
Management Equity Incentive Plan | Class E
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class C, class D, and class E vesting thresholds				300.00%
Management Equity Incentive Plan | Common Class C, Class D, Class E Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		0.4		$ 1
Compensation costs not yet recognized		8.9		8.9
Stock-based compensation expense reversed		0.1		$ 0.2
Management Equity Incentive Plan | Common Class C, Class D, Class E Stock | Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		9
Management Equity Incentive Plan | Common Class C, Class D, Class E Stock | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 1.5

STOCK BASED COMPENSATION - Sc63

STOCK BASED COMPENSATION - Schedule of Plan Activity (Details) - Stock-based Compensation - Management Equity Incentive Plan	6 Months Ended
	Apr. 30, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	84,700
Forfeited (in shares)	(438)
Ending balance (in shares)	84,262
Weighted Average Fair Value
Beginning balance (in USD per share) | $ / shares	$ 687.27
Forfeited (in USD per share) | $ / shares	870.09
Ending balance (in USD per share) | $ / shares	$ 686.32
Class B
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	59,290
Forfeited (in shares)	(288)
Ending balance (in shares)	59,002
Class C
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	8,470
Forfeited (in shares)	(50)
Ending balance (in shares)	8,420
Class D
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	8,470
Forfeited (in shares)	(50)
Ending balance (in shares)	8,420
Class E
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	8,470
Forfeited (in shares)	(50)
Ending balance (in shares)	8,420

STOCK BASED COMPENSATION - Fair

STOCK BASED COMPENSATION - Fair Value Assumptions (Details) - Management Equity Incentive Plan	6 Months Ended
	Apr. 30, 2017
Stock-based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate (in percent)	0.90%
Expected volatility (in percent)	41.60%
Estimated years to exit event	2 years 357 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate (in percent)	1.60%
Expected volatility (in percent)	38.10%
Estimated years to exit event	6 years
Dividend yield (in percent)	0.00%

STOCK BASED COMPENSATION - Rest

STOCK BASED COMPENSATION - Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 26, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 7	$ 2	$ 11	$ 3
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted (in shares)			1,028,534
Stock-based compensation expense	$ 4	$ 0	$ 5.3	$ 0
IPO | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in USD per share)					$ 24.79
Management | IPO | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted (in shares)			1,366,383
Director | IPO | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted (in shares)			41,635
Ordinary Shares | Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in USD per share)	$ 27.15		$ 27.15
Shares issued during period (in shares)			70,700
Treasury shares acquired, at cost (in shares)			(8,528)
Stock-based compensation expense	$ 3		$ 4.3
Compensation costs not yet recognized	$ 29.5		$ 29.5

STOCK BASED COMPENSATION - Summ

STOCK BASED COMPENSATION - Summary of Restricted Stock Units (Details) - Restricted Stock Units	6 Months Ended
	Apr. 30, 2017$ / sharesshares
Restricted Share Units
Beginning balance (in shares)	450,184
Granted (in shares)	1,028,534
Vested (in shares)	(70,700)
Forfeitures (in shares)	0
Ending balance (in shares)	1,408,018
Weighted Average Grant Date Fair Value
Beginning balance (in USD per share) | $ / shares	$ 21
Granted (in USD per share) | $ / shares	26.46
Vested (in USD per share) | $ / shares	21
Ending balance (in USD per share) | $ / shares	$ 24.79

STOCK BASED COMPENSATION - Stoc

STOCK BASED COMPENSATION - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	Jul. 26, 2016	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 7	$ 2	$ 11	$ 3
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grants (in shares)				726,166
Stock-based compensation expense		1.1	$ 0	$ 1.5	$ 0
Compensation costs not yet recognized		8.1		8.1
Stock Options | EBITDA Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		0.3
Compensation costs not yet recognized		5.6		5.6
IPO | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grants (in shares)	1,747,750
Share price (in USD per share)	$ 23.28
Estimate fair value of stock options (in USD per share))	$ 9.08
Stock-based compensation expense		$ 0.8		$ 1.2
IPO | Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grants (in shares)	1,033,465
Vesting period	3 years

STOCK BASED COMPENSATION - Sc68

STOCK BASED COMPENSATION - Schedule of Stock Options (Details) - Stock Options	6 Months Ended
	Apr. 30, 2017$ / sharesshares
Stock Options
Beginning balance (in shares)	1,021,584
Granted (in shares)	726,166
Forfeited (in shares)	0
Exercised (in shares)	0
Ending balance (in shares)	1,747,750
Weighted Average Fair Value
Beginning balance (in USD per share) | $ / shares	$ 8.29
Granted (in USD per share) | $ / shares	10.18
Ending balance (in USD per share) | $ / shares	$ 9.08

FINANCIAL INSTRUMENTS, FAIR V69

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Summary of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016	Jan. 31, 2016	Jan. 29, 2016
Assets measured at fair value
Available-for-sale securities	$ 1.4	$ 1.4
Held-for-trading securities	1.5	1.4
Total assets	2.9	2.8
Liabilities measured at fair value
Earnout liability	37.9	33.8	$ 31.1	$ 36
Total liabilities	39.7	36.5
Foreign exchange forward contracts
Liabilities measured at fair value
Foreign exchange forward contracts	1.8	2.7
Level 1
Assets measured at fair value
Available-for-sale securities	1.4	1.4
Held-for-trading securities	0	0
Total assets	1.4	1.4
Liabilities measured at fair value
Earnout liability	0	0
Total liabilities	0	0
Level 1 | Foreign exchange forward contracts
Liabilities measured at fair value
Foreign exchange forward contracts	0	0
Level 2
Assets measured at fair value
Available-for-sale securities	0	0
Held-for-trading securities	1.5	1.4
Total assets	1.5	1.4
Liabilities measured at fair value
Earnout liability	0	0
Total liabilities	1.8	2.7
Level 2 | Foreign exchange forward contracts
Liabilities measured at fair value
Foreign exchange forward contracts	1.8	2.7
Level 3
Assets measured at fair value
Available-for-sale securities	0	0
Held-for-trading securities	0	0
Total assets	0	0
Liabilities measured at fair value
Earnout liability	37.9	33.8
Total liabilities	37.9	33.8
Level 3 | Foreign exchange forward contracts
Liabilities measured at fair value
Foreign exchange forward contracts	$ 0	$ 0

FINANCIAL INSTRUMENTS, FAIR V70

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Schedule of Derivative Financial Instruments and Investments Classification on Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Derivatives, Fair Value [Line Items]
Available-for-sale securities	$ 1.4	$ 1.4
Held-for-trading securities	1.5	1.4
Total assets	2.9	2.8
Total liabilities	39.7	36.5
Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Foreign exchange forward contracts (Derivative liabilities)	1.8	2.7
Investments
Derivatives, Fair Value [Line Items]
Available-for-sale securities	1.4	1.4
Held-for-trading securities	1.5	1.4
Accounts payable and accrued liabilities | Foreign exchange forward contracts
Derivatives, Fair Value [Line Items]
Foreign exchange forward contracts (Derivative liabilities)	1.8	2.7
Other long-term liabilities
Derivatives, Fair Value [Line Items]
Earnout liability	$ 37.9	$ 33.8

FINANCIAL INSTRUMENTS, FAIR V71

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Fair Value Measurements Narrative (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2017	Oct. 31, 2016
Fair Value Disclosures [Abstract]
Gross unrealized loss	$ 2	$ 2.7
Gross unrealized gain	$ 0.2	$ 0.1

FINANCIAL INSTRUMENTS, FAIR V72

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Schedule of Fair Values and Carrying Values of Long-term Debt (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Fair Value
Liabilities:
Long-term debt, including current portion	$ 2,179.3	$ 2,156.8
Fair Value | Level 1
Liabilities:
Long-term debt, including current portion	0	0
Fair Value | Level 2
Liabilities:
Long-term debt, including current portion	2,179.3	2,156.8
Fair Value | Level 3
Liabilities:
Long-term debt, including current portion	0	0
Carrying Value
Liabilities:
Long-term debt, including current portion	$ 2,134	$ 2,119

FINANCIAL INSTRUMENTS, FAIR V73

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Foreign Exchange Contracts and Other Arrangements Narrative (Details) $ in Millions	Jan. 29, 2016USD ($)tranche	Apr. 30, 2017USD ($)CAD / $	Apr. 30, 2016USD ($)	Apr. 30, 2017USD ($)CAD / $	Apr. 30, 2016USD ($)	Oct. 31, 2016USD ($)	Jan. 31, 2016USD ($)
Derivatives, Fair Value [Line Items]
Contingent consideration	$ 36	$ 37.9		$ 37.9		$ 33.8	$ 31.1
Capital transaction	36
Adjusted EBITDA growth rate (as percent)				10.00%
Maximum payment under Earnout Agreement	60
Minimum payment under Earnout Agreement	$ 25
Income recognized from change in fair value in earnout liability			$ 4.9
Number of tranches | tranche	3
Level 3
Derivatives, Fair Value [Line Items]
Contingent consideration		$ 37.9		$ 37.9		33.8
Tranche one
Derivatives, Fair Value [Line Items]
Consideration transferred	$ 25
Tranche two
Derivatives, Fair Value [Line Items]
Contingent consideration	25
Adjusted EBITDA value	98
Tranche three
Derivatives, Fair Value [Line Items]
Contingent consideration	10
Adjusted EBITDA value	$ 110
Designated as hedging instruments | Foreign Exchange Forward Issued January 2017 | Canada
Derivatives, Fair Value [Line Items]
Average exchange rate | CAD / $		1.3254		1.3254
Unrealized loss recorded in accumulated other comprehensive income in shareholders' deficit, net of associated income tax		$ (1.8)
Designated as hedging instruments | Foreign Exchange Forward Issued January 2017 | Canada | Short
Derivatives, Fair Value [Line Items]
Aggregate amount to sell		64		$ 64
Earnout | Level 3
Derivatives, Fair Value [Line Items]
Earnout liability		37.9		37.9		$ 33.8
Income (expense) recognized from change in fair value earn out liability		$ (0.5)	$ (1.2)	$ (4.1)	$ 3.7
Asset volatility rate (as percent)				30.00%
Asset beta				0.9
Change in asset volatility (as percent)				1.00%
Change in liability amount due to asset volatility change				$ 0.3
Change in asset beta				0.1
Change in liability amount due to asset beta change				$ 0.3

FINANCIAL INSTRUMENTS, FAIR V74

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Earnout Liability Activity (Details) - Level 3 - Earnout - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Roll Forward]
Earnout liability, beginning balance			$ 33.8
Change in fair value	$ 0.5	$ 1.2	4.1	$ (3.7)
Earnout liability, ending balance	$ 37.9		$ 37.9

FINANCIAL INSTRUMENTS, FAIR V75

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Foreign Exchange Risk Narrative (Details) € in Millions, $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2017USD ($)	Oct. 31, 2016USD ($)	Apr. 30, 2017EUR (€)
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Cumulative unrealized exchange gains	$ 0.2	$ 0.1
Foreign credit agreement
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Long-term debt, including current portion, carrying value | €			€ 463.1
Cumulative unrealized exchange gains	$ 74.7
Canada
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Potential increase/decrease in exchange rate impacting operating income, percentage	10.00%
Potential increase/decrease in exchange rate impacting operating income, value	$ 5.8
Percent of cash flow exposures covered by hedges			68.00%
Geographic Concentration Risk | Canada | Cash receipts from operations in U.S. dollars
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration risk, percentage (as percent)	90.00%
Geographic Concentration Risk | Canada | Cash outflows in U.S. dollars
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Concentration risk, percentage (as percent)	15.00%

FINANCIAL INSTRUMENTS, FAIR V76

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) (Details) - Net investment hedge - Foreign exchange contract - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange (loss) gain for the period from net investment hedge	$ (4.6)	$ (29)	$ 4	$ (21)
Release of ineffective portion of net investment hedge to consolidated statement of operations	0	3.3	0	2.2
Net (loss) gain to other comprehensive income for the period related to net investment hedge	(4.6)	(25.7)	4	(18.8)
Intercompany loans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net loss to other comprehensive income (loss) for the period related to foreign exchange	$ 0	$ 3.8	$ 0	$ 3

FINANCIAL INSTRUMENTS, FAIR V77

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Credit Risk (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016
Fair Value Disclosures [Abstract]
Deposits held	$ 4.1	$ 4.3

FINANCIAL INSTRUMENTS, FAIR V78

FINANCIAL INSTRUMENTS, FAIR VALUE AND RISK MANAGEMENT - Liquidity Risk (Details) - USD ($) $ in Millions	Apr. 30, 2017	Oct. 31, 2016	Apr. 30, 2016	Oct. 31, 2015
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 92.7	$ 165	$ 184.7	$ 328.7
Liquidity risk
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Cash and cash equivalents	92.7
Liquidity risk | Line of credit
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Undrawn lines of credit available	$ 209.3

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
	Apr. 30, 2017segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	3

SEGMENT INFORMATION - Segment R

SEGMENT INFORMATION - Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Segment Reporting Information [Line Items]
Revenues	$ 483.4	$ 468.6	$ 940.8	$ 874.5
Adjusted EBITDA	94.2	98	176.7	157
Depreciation and amortization	34.3	27	61.9	53.5
Capital expenditures	40.2	30.9	99.2	95.1
Operating Segments | DPS
Segment Reporting Information [Line Items]
Revenues	297.2	287.4	572.4	545.9
Adjusted EBITDA	77.4	72.7	138.8	127.8
Depreciation and amortization	15.4	14.9	30.7	29.7
Capital expenditures	19.5	11.7	56.4	56.7
Operating Segments | PDS
Segment Reporting Information [Line Items]
Revenues	57.8	53.4	110.1	101.9
Adjusted EBITDA	18.4	16.7	34.7	30.5
Depreciation and amortization	1.9	1.3	3.7	2.5
Capital expenditures	1.7	5.9	3.1	15.6
Operating Segments | DSS
Segment Reporting Information [Line Items]
Revenues	129.2	127.9	259.1	226.8
Adjusted EBITDA	26.1	30.8	58.1	45.6
Depreciation and amortization	16.1	10.2	25.8	20.1
Capital expenditures	11.6	9	29.5	16.3
Other | Other
Segment Reporting Information [Line Items]
Revenues	0	0	0	0
Adjusted EBITDA	(27.5)	(22.2)	(54.7)	(46.9)
Depreciation and amortization	0.9	0.6	1.7	1.2
Capital expenditures	7.4	4.3	10.2	6.5
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues	(0.8)	$ (0.1)	(0.8)	$ (0.1)
Adjusted EBITDA	$ (0.2)		$ (0.2)

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Adjusted EBITDA (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Segment Reporting Information [Line Items]
Total Adjusted EBITDA	$ 94.2	$ 98	$ 176.7	$ 157
Depreciation and amortization	(34.3)	(27)	(61.9)	(53.5)
Repositioning expenses	(2.2)	(1.3)	(3.5)	(2.5)
Acquisition and integration costs	(8.1)	(7.6)	(11.6)	(10.2)
Interest expense, net	(30.8)	(42.6)	(59)	(86.4)
Benefit from (provision for) income taxes	1.5	(0.7)	22.8	0
Refinancing expenses	(6.3)	0	(6.3)	0
Operational initiatives related consulting costs	(1.4)	(1.9)	(2.5)	(3.3)
IPO costs	0	(0.4)	0	(0.8)
Acquisition related litigation expenses	(3.7)	(0.9)	(6)	(1.9)
Stock based compensation expense	(7)	(2)	(11)	(3)
FDA remediation costs	0	(10.1)	0	(18.5)
Environmental remediation costs	0	0	(3.7)	0
Bargain purchase gain	26.4	0	26.4	0
Other	(0.7)	(1.6)	(4.5)	5
Net income (loss) from continuing operations	27.6	$ 1.9	55.9	$ (18.1)
Swindon Wind Down
Segment Reporting Information [Line Items]
Inventory Write-down	$ 0.4		$ 1.1

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Revenue, Capital Assets and Goodwill, by Country (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Oct. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 483.4	$ 468.6	$ 940.8	$ 874.5
Capital Assets	1,169.3	945.8	1,169.3	945.8	$ 983.6
Goodwill	281.4	282.1	281.4	282.1	$ 281.6
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	4.2	5.1	11.2	12.4
Capital Assets	100.1	100.8	100.1	100.8
Goodwill	2.5	2.8	2.5	2.8
U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	282.8	317.6	564.7	589.4
Capital Assets	687.6	487.3	687.6	487.3
Goodwill	269.4	269.4	269.4	269.4
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	167.9	124.8	320.7	236.7
Capital Assets	367.5	341.6	367.5	341.6
Goodwill	7.4	7.7	7.4	7.7
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	28.5	21.1	44.2	36
Capital Assets	14.1	16.1	14.1	16.1
Goodwill	$ 2.1	$ 2.2	$ 2.1	$ 2.2

REPOSITIONING EXPENSES - Narrat

REPOSITIONING EXPENSES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jan. 31, 2017	Oct. 31, 2016	Jan. 31, 2016	Oct. 31, 2015
Restructuring Cost and Reserve [Line Items]
Repositioning expenses	$ 1.8	$ 1.3	$ 2.4	$ 2.5
Restructuring Reserve	4.9	$ 3.4	4.9	$ 3.4	$ 4.6	$ 5.4	$ 4.9	$ 22.9
Other Restructuring
Restructuring Cost and Reserve [Line Items]
Repositioning expenses	1.8
Inventory Reserve For Three Months Ended | Swindon Wind Down
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0.4		0.4
Inventory Reserve For Six Months Ended | Swindon Wind Down
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 1.1		$ 1.1

REPOSITIONING EXPENSES - Schedu

REPOSITIONING EXPENSES - Schedule of Repositioning Expenses and Charges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Restructuring Reserve [Roll Forward]
Total repositioning liability at beginning of period	$ 4.6	$ 4.9	$ 5.4	$ 22.9
Repositioning expenses	1.8	1.3	2.4	2.5
Repositioning expenses paid	(1.6)	(3.1)	(3.1)	(21.8)
Foreign exchange	0.1	0.3	0.2	(0.2)
Total repositioning liability at end of period	4.9	3.4	4.9	3.4
Employee-related expenses
Restructuring Reserve [Roll Forward]
Repositioning expenses	1.8	1.6	2.4	2.8
Consulting, professional and project management costs
Restructuring Reserve [Roll Forward]
Repositioning expenses		(0.3)		(0.3)
Operating Segments | DPS
Restructuring Reserve [Roll Forward]
Repositioning expenses		1.3		2.5
Operating Segments | DPS | Employee-related expenses
Restructuring Reserve [Roll Forward]
Repositioning expenses	1.7	1.6	1.9	2.8
Operating Segments | DPS | Consulting, professional and project management costs
Restructuring Reserve [Roll Forward]
Repositioning expenses		(0.3)		(0.3)
Operating Segments | PDS
Restructuring Reserve [Roll Forward]
Repositioning expenses		0		0
Operating Segments | PDS | Employee-related expenses
Restructuring Reserve [Roll Forward]
Repositioning expenses	0	0	0	0
Operating Segments | PDS | Consulting, professional and project management costs
Restructuring Reserve [Roll Forward]
Repositioning expenses		0		0
Operating Segments | DSS
Restructuring Reserve [Roll Forward]
Repositioning expenses		0		0
Operating Segments | DSS | Employee-related expenses
Restructuring Reserve [Roll Forward]
Repositioning expenses	0	0	0	0
Operating Segments | DSS | Consulting, professional and project management costs
Restructuring Reserve [Roll Forward]
Repositioning expenses		0		0
Other | Other
Restructuring Reserve [Roll Forward]
Repositioning expenses		0		0
Other | Other | Employee-related expenses
Restructuring Reserve [Roll Forward]
Repositioning expenses	$ 0.1	0	$ 0.5	0
Other | Other | Consulting, professional and project management costs
Restructuring Reserve [Roll Forward]
Repositioning expenses		$ 0		$ 0

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2016	Feb. 29, 2016	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Oct. 31, 2016	Oct. 31, 2015
Related Party Transaction [Line Items]
Cash distribution from Banner Life Services					$ 0	$ 1.3
Return on capital					0	2.3
Affiliated entity | JLL Partners Inc. and DSM | Business Services
Related Party Transaction [Line Items]
Expenses from transactions with related party			$ 0.1	$ 0.1	0.1	0.2
Accounts payable, related parties			0.1		0.1		$ 0
Affiliated entity | Koninklijke DSM | Shared Service Functions
Related Party Transaction [Line Items]
Expenses from transactions with related party			1.9	2.5	5.1	5.2
Revenue for services from related parties			0.1	0.8	0.3	0.9
Accounts payable, related parties			1.7		1.7		0.2
Accounts receivable, related parties			0.1		0.1		0.4
Affiliated entity | Banner Life Sciences | Shared Service Functions
Related Party Transaction [Line Items]
Revenue for services from related parties			0.7	1.4	0.7	7.9
Accounts receivable, related parties			1.2		1.2		1.1
Equity Method Investee
Related Party Transaction [Line Items]
Equity method investment values			8.3		8.3		8.7
Equity method gain/(loss)			(0.2)	(0.4)	(0.3)	1.5
Equity Method Investee | Banner Life Sciences
Related Party Transaction [Line Items]
Equity method investment values			2.5		2.5		2.9	$ 5
Cash distribution from Banner Life Services	$ 2.4
Equity method gain/(loss)			(0.2)	(0.5)	(0.3)	1.3
Equity Method Investee | Percivia
Related Party Transaction [Line Items]
Equity method investment values			$ 5.7		$ 5.7		5.7
Ownership percentage (as percent)			50.00%		50.00%
Return on capital		$ 1.2
Equity method gain/(loss)			$ 0	$ 0.1	$ 0	$ 0.2
Equity Method Investee | ChemiePark
Related Party Transaction [Line Items]
Equity method investment values			$ 0.1		$ 0.1		$ 0.1
Ownership percentage (as percent)			47.50%		47.50%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Apr. 30, 2017	Jan. 31, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Valuation Allowance [Line Items]
Provision for (benefit from) income taxes	$ (1.5)		$ 0.7	$ (22.8)	$ 0
Deferred income taxes				$ 29.7	$ 0.9
Patheon Biologics LLC
Valuation Allowance [Line Items]
Deferred income taxes	$ 3.5	$ 28.3

OTHER INFORMATION - Foreign Exc

OTHER INFORMATION - Foreign Exchange (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Other Information [Abstract]
Foreign exchange loss, net	$ 0.7	$ 7.1	$ 5.5	$ 11.4

OTHER INFORMATION - Management

OTHER INFORMATION - Management Incentive Plan (Details) - Management Long-Term Incentive Plan - USD ($) $ in Millions	Mar. 11, 2014	Apr. 30, 2017
Loss Contingencies [Line Items]
Threshold percentage of ownership of equity securities for exit event	20.00%
Percentage of excess capital contributions received to trigger an Exit Event	250.00%
Number of days to determine plan details	90 days
Value of LTIP units granted		$ 9.6
Vesting period		5 years
Payments made due to qualified terminations		$ 0.2

OTHER INFORMATION - Contingenci

OTHER INFORMATION - Contingencies (Details) € in Millions	1 Months Ended		6 Months Ended
	Nov. 30, 2015EUR (€)plaintiff	Oct. 31, 2011plaintiff	Apr. 30, 2017
Loss Contingencies [Line Items]
Number of plaintiffs	113	115
Number of plaintiff actions		2
Number of named plaintiffs		2
Italy | Italian client dispute
Loss Contingencies [Line Items]
Amount of penalty per day sought by client | €	€ 0.2
Banner Acquisition | Softgel Services | Service concentration risk | Sales revenue
Loss Contingencies [Line Items]
Concentration risk, percentage (generally less than) (as percent)			10.00%

OTHER INFORMATION - Supplementa

OTHER INFORMATION - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Condensed Cash Flow Statements, Captions [Line Items]
Increase in capital lease obligations	$ 1	$ 0
Assumption of earnout liability from the Partnership
Condensed Cash Flow Statements, Captions [Line Items]
Assumption of earnout liability from the Partnership	0	36
Treasury stock purchases to satisfy certain tax withholdings
Condensed Cash Flow Statements, Captions [Line Items]
Assumption of earnout liability from the Partnership	$ 0.1	$ 0

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Thermo Fisher - Subsequent event $ / shares in Units, $ in Billions	May 15, 2017USD ($)$ / shares
Subsequent Event [Line Items]
Share price (in USD per share) | $ / shares	$ 35
Amount of cash and associated inventory and spare parts transferred	$ 7.2
Liability assumed as part of business combination	$ 2